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1  SUMMARY     
 
Macrophages show a remarkable functional plasticity, which enables them to 
change  their  phenotype  in  response  to  environmental  signals.  They  are  key 
players during infection by initiating inflammation through the release of pro-
inflammatory mediators. Furthermore, macrophages contribute to the resolution 
of  inflammation  by  phagocytosis  of  apoptotic  granulocytes.  Phagocytosis  of 
apoptotic cells (AC) induces an anti-inflammatory phenotype in macrophages 
and protects them against apoptosis. However, mechanistic details provoking 
these phenotype alterations are incompletely understood. Therefore, the aim of 
my  Ph.D.  thesis  was  to  investigate  the  molecular  basis  of  anti-inflammatory 
macrophage polarization.   
In the first part of my studies, I investigated the expression of heme oxygenase 
(HO)-1 in macrophages following treatment with supernatants from AC. HO-1 
catalyzes the first and rate-limiting step of heme degradation and potentially 
bears anti-inflammatory as well as anti-apoptotic potential. I was able to show 
biphasic upregulation of  HO-1 by  AC  supernatants. The first  phase  of  HO-1 
induction at 6 h required activation of p38 MAPK and was accomplished by the 
bioactive lipid sphingosine-1-phosphate (S1P) engaging S1P receptor 1 (S1P1). 
However, the second wave of HO-1 induction at 24 h was attributed to autocrine 
signaling  of  vascular  endothelial  growth  factor  (VEGF)  A,  whose  expression 
was facilitated by S1P. The release of VEGFA from macrophages was STAT1-
dependent, whereas VEGFA itself acted on the macrophage HO-1 promoter via 
STAT1/STAT3 heterodimer binding. Knockdown of HO-1 revealed its relevance 
in  promoting  enhanced  expression  of  the  anti-apoptotic  proteins  B  cell 
leukemia/lymphoma-2 (Bcl-2) and B cell leukaemia/lymphoma-x long (Bcl-XL), 
as  well  as  the  anti-inflammatory  adenosine  receptor  A2A.  MHC  II  and 
indoleamine  2,3-dioxygenase  expression  were  also  affected  by  AC-
supernanatants, but were not HO-1 dependent.         
Unexpectedly,  S1P1  was  also  upregulated  following  treatment  with  AC 
supernatants. Thus, I considered whether S1P1 induction could specifically be 
mediated by alternative macrophage activating factors. The expression of S1P1 
was enhanced in the presence of the alternative activation stimuli IL-4 as well 1 Summary                                                                                                           2                                                                                   
as IL-10, whereas it was unchanged following incubations with LPS, interferon-g 
or  S1P.  My  next  aim  was  to  investigate  the  expression of the  different  S1P 
receptor isoforms in macrophages following treatment with supernatants form 
AC. While the expressions of S1P1 as well as S1P3 were induced by exposure 
to supernatants from AC, S1P2 expression was unaffected. As S1P1/3 and S1P2 
are  conflictively  involved  in  the  regulation  of  cell  migration,  I  asked  for  a 
correlation  between  increased  S1P  receptor  expression  and  enhanced 
migration  rate.  Indeed,  macrophages  showed  enhanced  motility  following 
treatment  with  supernatants  form  AC,  which  was  inhibited  in  S1P1  knockout 
macrophages.       
In summary, my findings indicate that HO-1, which is induced by AC-derived 
S1P, is critically involved in macrophage polarization towards an alternatively 
activated  macrophage  phenotype.  S1P1  seems  to  represent  a  central 
checkpoint during macrophage activation. On the one hand, S1P1 is induced by 
supernatants form AC and promotes migration of macrophages. On the other 
hand,  it  mediates  the  induction  of  HO-1,  which  is  accompanied  by  anti-
inflammatory  as  well  as  anti-apoptotic  signaling.  Furthermore,  my  studies 
provide  evidence  that  upregulation  of  HO-1  and  S1P1  in  macrophages  may 
contribute to the resolution of inflammation by establishing an anti-inflammatory 
macrophage  phenotype  and  provoking  macrophage  migration  along  the 
vascular S1P gradient out of an inflammatory environment into the lymph.  2 Zusammenfassung                                                                                           3                                                                                                          
2  ZUSAMMENFASSUNG 
 
Makrophagen weisen eine bemerkenswerte funktionelle Plastizität auf, welche 
es ihnen ermöglicht, ihren Phänotyp als Antwort auf Umweltreize zu ändern. Sie 
spielen  eine  zentrale  Rolle  während  der  Infektion,  indem  sie  die 
Entzündungsreaktion  durch  die  Freisetzung  von  pro-inflammatorischen 
Mediatoren  initiieren.  Darüber  hinaus  tragen  Makrophagen  durch  die 
Phagozytose  apoptotischer  Zellen  zur  Auflösung  der  Entzündung  bei. 
Phagozytose von apoptotischen Zellen induziert einen anti-inflammatorischen 
Phänotyp  in  Makrophagen  und  schützt  sie  vor  Apoptose.  Jedoch  sind  die 
mechanistischen Details, welche diese Phänotyp-Veränderungen bewirken, nur 
unvollständig  bekannt.  Daher  war  es  das  Ziel  meiner  Doktorarbeit,  die 
molekulare  Basis  der  anti-inflammatorischen  Makrophagen-Polarisierung  zu 
untersuchen. 
Im  ersten  Teil  meiner  Studien  untersuchte  ich  die  Expression  der  Häm 
Oxygenase  (HO)-1  in  Makrophagen  nach  Behandlung  mit  Überständen  von 
apoptotischen Zellen. Die HO-1 katalysiert den ersten und limitierenden Schritt 
des  Häm-Abbaus  und  weist  anti-inflammatorisches  sowie  anti-apoptotisches 
Potential auf. Ich war in der Lage eine biphasische Induktion der HO-1 durch 
Überstände von apoptotischen Zellen zu zeigen. Die erste Phase der HO-1-
Induktion nach 6 h erforderte die Aktivierung der p38 MAPK und wurde durch 
Interaktion des bioaktiven Lipids Sphingosin-1-Phosphat (S1P) mit dem S1P-
Rezeptor 1 (S1P1) vermittelt. Die zweite Welle der HO-1-Induktion nach 24 h 
war dem „vascular endothelial growth factor“ (VEGF) A zuzuschreiben, dessen 
Expression durch S1P ausgelöst wurde. Während die Freisetzung von VEGFA 
aus  Makrophagen  STAT1-abhängig  war,  wirkte  VEGFA  autokrin  über 
STAT1/STAT3-Heterodimer-Bindung auf den HO-1-Promotor. Ein Knockdown 
der HO-1 enthüllte ihre Bedeutsamkeit für der Förderung der Expression der 
anti-apoptotischen  Proteine  „B  cell  leukemia/lymphoma-2“  (Bcl-2) und  „B  cell 
leukaemia/lymphoma-x  long“  (Bcl-XL)  sowie  des  anti-inflammatorischen 
Adenosin-Rezeptors A2A. Die Expression des MHC II und der Indolamin 2,3-
dioxygenase  wurden  auch  von  Überständen  von  apoptotischen  Zellen 
beeinflusst, waren aber nicht HO-1-abhängig.       2 Zusammenfassung                                                                                           4                                                                                                          
Unerwartet  war  auch  der  S1P1  nach  Behandlung  mit  Überstanden  von 
apoptotischen Zellen hochreguliert. Folglich erwägte ich, ob die Induktion des 
S1P1 spezifisch durch Faktoren vermittelt werden konnte, welche Makrophagen 
alternativ aktivieren. Die Expression des S1P1 war in Gegenwart der alternativ-
aktivierenden  Stimuli  IL-4  und  IL-10  gesteigert,  hingegen  war  sie  nach 
Inkubation mit LPS, Interferon-g oder S1P unverändert. Mein nächstes Ziel war 
es,  die  Expressionsrate  der  verschiedenen  S1P-Rezeptor-Isoformen  in 
Makrophagen nach Behandlung mit Überständen von apoptotischen Zellen zu 
untersuchen.  Während  die  Expression  des  S1P1  sowie  des  S1P3  durch 
Stimulation mit Überständen von apoptotischen Zellen induziert waren, war die 
Expression des S1P2 unberührt. Da der S1P1/3 und der S1P2 gegensätzlich in 
die  Regulation  der  Zell-Migration  involviert  sind,  fragte  ich  nach  einer 
Korrelation  zwischen  der  erhöhten  S1P-Rezeptor-Expression  und  einer 
gesteigerter Migrationsrate. In der Tat, wiesen Makrophagen nach Behandlung 
mit Überständen von apoptotischen Zellen eine gesteigerte Motilität auf, welche 
in S1P1-Knockout-Makrophagen gehemmt war. 
Zusammenfassend zeigen meine Entdeckungen, dass die HO-1, welche durch 
von  apoptotischen  Zellen  freigesetztes  S1P  induziert  wird,  kritisch  in  die 
Makrophagen-Polarisierung  in  Richtung  eines  alternativ-aktivierten 
Makrophagen-Phänotyps  involviert  ist.  S1P  scheint  einen  zentralen 
Kontrollpunkt  während  der  Makrophagen-Aktivierung  darzustellen.  Einerseits 
wird der S1P1 durch Überstände von apoptotischen Zellen induziert und fördert 
die Migration der Makrophagen. Andererseits vermittelt er die Induktion der HO-
1,  welche  anti-inflammatorische  sowie  anti-apoptotische  Antworten  auslöst. 
Darüber hinaus liefern meine Studien Hinweise dafür, dass die Induktion der 
HO-1  und  des  S1P1  in  Makrophagen  die  Etablierung  eines  anti-
inflammatorischen  Makrophagen-Phänotyps  und  das  Auslösen  von 
Makrophagen-Migration  entlang  des  vaskulären  S1P-Gradienten  aus  der 
entzündlichen Umgebung in die Lymphe bewirkt, und somit zur Auflösung einer 
Entzündung beitragen kann.   3 Introduction                                                                                                     5                                                                                                                                       
3  INTRODUCTION 
 
3.1  Cell death  
 
In metazoans, tissue homeostasis is ensured by two central mechanisms. While 
‘new’ cells are generated during the cell cycle of progenitor cells, followed by 
their differentiation into specialists, redundant, damaged or infected cells are 
eliminated by cell death (1, 2). 
A  vast  number  of  distinct  modes  of  cell  death  associated  with  varying 
morphological  characteristics  has  been  reported.  These  modes  include 
necrosis,  autophagy  and  mitotic  catastrophe  (3).  However,  in  multicellular 
organisms apoptosis, a physiological and programmed form of cell death, is the 
predominant mode of cell death (4).   
In  1842,  naturally  occurring  cell  death  was  first  described  by  Carl  Vogt  (5). 
However,  after  a  long  period  of  neglect,  more  than  one  decade  later  this 
process was termed apoptosis, the Greek word for the fall of leaves in autumn, 
by Kerr, Wyllie and Currie (6).  
The characteristic and stereotypical morphology of apoptosis involves nuclear 
chromatin condensation and fragmentation, cell shrinkage and controlled cell 
disintegration through the formation of membrane vesicles, so-called ‘apoptotic 
bodies’, whose membrane integrity is maintained (6, 7). Apoptosis is a tightly 
regulated  means,  by  which  cells  actively  orchestrate  their  own  demise  (8). 
Apoptotic cells (AC) provide signals for the rapid clearance of apoptotic debris 
by professional phagocytes in vivo. Thus, ‘quiet clearance’ of this process is 
ensured (9).  
In contrast, necrosis classically has been defined as accidental or murderous 
cell death owing, for example, to noxious insults such as heat, irradiation or 
toxins  provoking  uncontrolled  cell  swelling  and  membrane  rupture.  The 
consequence is leakage of cytosolic, organelle and nuclear components into the 
interstitial  space,  which  may  cause  severe  inflammation.  Membrane 
disintegration is also observed during secondary necrosis, which is a result of 
defective  phagocytosis  of  AC.  Secondary  necrosis  occurs  in  vivo  when  the 3 Introduction                                                                                                     6                                                                                                                                       
number of apoptotic cells exceeds the local capacity for phagocyte-mediated 
clearance (10, 11).  
 
 
3.1.1  Induction of apoptosis 
 
Caspases,  a  family  of  cystein  proteases,  which  cleave  their  substrates  after 
aspartic acid residues, play a central role in the induction of apoptotic cell death 
(12). They are highly conserved throughout evolution and can be found even in 
hydra, a member of the ancient metazoan phylum Cnidaria (13). Caspases are 
synthesized as enzymatically inert zymogens, so-called pro-caspases. They are 
usually  activated  upon  proteolytic  processing  at  cleavage  sites  containing 
aspartic acid residues by other active caspases (14). This activation strategy is 
termed ‘caspase cascade’ and involves the activation of effector caspases by 
initiator caspases to amplify and integrate pro-apoptotic signals (15). Activation 
of the main initiator caspases caspase-8 and caspase-9 defines the sensitive 
step  in  apoptosis  induction.  Starting  from  this  point,  two  principally  different, 
eventually converging pathways can be pursued (16) (Figure 1).  
 
 
3.1.1.1   Extrinsic pathway of apoptosis induction 
The extrinsic cell death pathway starts with coupling of death ligands, which 
belong to the TNF family, to their specific death receptors on the cell surface 
(17). Receptor ligation is followed by the recruitment of adapter proteins such as 
fas-associated  death  domain  and  pro-caspase-8  to  form  a  complex  termed 
death-inducing  signaling  complex  (4,  18).  Consequently,  pro-caspase-8  is 
cleaved to yield enzymatically active caspase-8, which then processes effector 
caspases including caspase-3, -6 and -7. Activation of these caspases finally 
results in the execution of apoptosis, as they initiate the cleavage of different 
substrates such as DNA repair enzymes, structural proteins and endonuclease 
inhibitors (4).   
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3.1.1.2   Intrinsic pathway of apoptosis induction 
Reactive oxygen species (ROS) and/or reactive nitrogen species, DNA damage 
or growth factor withdrawal are initiators of the intrinsic cell death pathway (19-
21). Cytochrome c is released from mitochondria in response to these stimuli, 
which then is accompanied by the activation of caspase-9 (19). Members of the 
B cell leukemia/lymphoma-2 (Bcl-2) protein family serve to tightly regulate the 
leakage  of  pro-apoptotic  cytochrome  c  from  mitochondria.  The  Bcl-2  protein 
family includes proteins with pro- as well as anti-apoptotic properties and thus, 
proteins of this family are considered as essential regulators of apoptosis (22). 
Based on their domain architecture, the members of the Bcl-2 protein family 
were classified into three distinct groups (23). While the anti-apoptotic members 
such  as  Bcl-2  and  B cell  leukaemia/lymphoma-x  long  (Bcl-XL)  share  all  four 
Bcl-2  homology  domains  (BH1-BH4),  the  pro-apoptotic  ones  like  Bcl-2-
associated protein x or Bcl-2 homologous antagonist/killer share three domains 
(BH1-BH3).  The  members  of  the  so-called  BH-3-only  proteins  like  Bcl-2 
antagonist  of  cell  death,  Bcl-2-interacting
  mediator  of  cell  death  or  BH3-
interacting domain death agonist (Bid) possess only the BH3 domain (24). As 
Bcl-2  proteins  form  heterodimers  between  pro-  and  anti-apoptotic  family 
members to neutralize each other, the balance between pro- and anti-apoptotic 
Bcl-2 proteins determines cell fate (15). Oversimplyfied, BH3-only proteins are 
activated by intrinsic death stimuli, which enables them to inhibit anti-apoptotic 
or  to  activate  pro-apoptotic  Bcl-2  family  members  with  high  specifity.  As  a 
consequence,  the  mitochondrial  outer  membrane  is  permeabilized  and 
cytochrome  c  is  released  into  the  cytosol  (25).  Subsequently,  cytochrome  c 
induces ATP-dependent heptamerization of apoptotic protease activating factor 
to form a ‘wheel-shaped’ signaling platform, which is termed the apoptosome 
(26). After recruitment of pro-caspase-9 to the apoptosome and its activation, 
caspase-9  activates  effector  caspases  (27).  Notably,  dependent  on  cell  type 
and apoptosis-inducing stimulus, a connection between the extrinsic and the 
intrinsic cell death pathway has been observed. Caspase-8, which is activated 
via the extrinsic pathway can promote cleavage of the BH3-only protein Bid. 
The resulting truncated Bid can insert into the mitochondrial outer membrane to 
induce its permeabilization and thus activate the intrinsic pathway of apoptosis 
induction (28).   3 Introduction                                                                                                     8                                                                                                                                       
 
 
Figure  1.  Induction  of  apoptosis.  Apoptosis  can  be  initiated  by  two  distinct  pathways.  The 
extrinsic pathway is initiated upon ligation of death receptors by specific death ligands. After 
recruitment  of  adapter  proteins  and  pro-caspase  8,  the  death-inducing  signaling  complex 
(DISC)  is  formed,  which  provokes  activation  of  caspase-8  via  proteolytic  cleavage  of  pro-
caspase 8. Caspase-8 then activates effector caspases resulting in the execution of apoptosis. 
Caspase-8 also may cross-activate the intrinsic death pathway, which is induced in response to 
growth factor withdrawal, DNA damage as well as irradiation and involves activation of Bcl-2 
homology  domain  (BH)3-only  members  of  the  B  cell  leukemia/lymphoma-2  (Bcl-2)  family. 
Thereupon, cytochrome c is released from mitochondria mainly  through  the action  of Bcl-2-
associated protein x (Bax) and Bcl-2 homologous antagonist/killer (Bak), which constitute pro-
apoptotic members of the Bcl-2 family. Anti-apoptotic members such as Bcl-2 can be inhibited 
by BH3-only proteins and can themselves inhibit pro-apoptotic members of the Bcl-2 family like 
Bax or Bak. Cytochrome c together with apoptotic protease activating factor-1 (APAF-1), ATP 
and pro-caspase 9 forms a heptameric complex termed the apoptosome. After the activation of 
caspase 9, effector caspases are activated, which results in the execution of apoptosis.          
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3.1.2  Diseases associated with apoptosis 
 
Recognition and clearance of AC by phagocytes is vital to the morphological 
shaping  of  tissues  during  development  and  plays  a  pivotal  role  in  the 
maintenance of tissue homeostasis, the regulation of the immune system and 
the resolution of inflammation (1, 29). Autoimmune diseases such as systemic 
lupus  erythematosus  may  arise  due  to  defects  in  AC  clearance  (30). 
Furthermore, disruption of the balance between cell proliferation and cell death 
can  result  in  the  development  of  neurodegenerative  disorders  such  as 
Alzheimer’s  disease  or  Parkinson’s  disease,  different  forms  of  cancer, 
autoimmune  disorders  such  as  rheumathoid  arthritis  and  increased 
susceptibility  to  bacterial  and  viral  infections  including  aquired  immune 
deficiency syndrome or ebola (31).  
 
 
3.2  Phagocytosis of apoptotic cells  
 
Clearance of AC represents the last step in the apoptotic program. Like the 
initiation and execution of apoptosis, also clearance of AC is a tightly regulated 
process. Three critical steps are traversed to ensure proper clearance of AC. 
First, phagocytes are attracted to the site of tissue damage. Second, AC are 
specifically  recognized  by  phagocytes.  Finally,  AC  or  their  fragments  are 
engulfed  by  phagocytes.  The  following  paragraphs  will  elaborate  on  the 
underling mechanisms of these steps.  
 
 
3.2.1  Attraction 
 
As  professional  phagocytes  such  as  macrophages  may  not  be  in  close 
proximity of dying cells, the secretion of chemoattractants by AC is of enormous 
importance  to  ensure  the  removal  of  AC  and  therefore  to  avoid  secondary 
necrosis (Figure 2). 3 Introduction                                                                                                     10                                                                                                                                       
 
 
Figure  2.  Phagocytosis  of  apoptotic  cells.  (A)  Apoptotic  cells  (AC)  secrete  a  multitude  of 
chemoattractants to direct macrophages (MF) to sites of tissue damage. (B) Different apoptotic 
cell-associated molecular patterns (ACAMP) allow phagocytes to distinguish viable or nerotic 
cells from AC. Bridging molecules (BM) often serve to strengthen the interaction of ACAMP and 
recognition receptors (RR) on the phagocyte surface. (C) Rearrangement of the phagocyte’s 
cytoskeleton finally results in a ‘zipper-like’ ingestion process.    
 
A plethora of chemoattractants, which are secreted by AC have been described. 
These  factors  include  thrombospondin  1,  lysophosphatidylcholine  and 
endothelial monocyte-activating polypeptide II (32-34). Thrombospondin 1 as a 
heterodimer with CD36 was also shown to serve as a signal for the recognition 
of  AC  (32).  Furthermore,  sphingosine-1-phosphate  (S1P)  is  secreted  by  AC 
(35). Besides its role in promoting monocyte/macrophage migration in vitro (36), 
S1P  was  reported  to  exert  potent  anti-inflammatory  activities,  as  will  be 
discussed  in  section  3.3.2.3.  AC  not  only  provide  attraction  signals  for 
mononuclear cells, but they also contribute to the resolution of inflammation by 
secreting  lactoferrin,  which  was  reported  to  potently  inhibit  granulocyte 
migration in vitro and in vivo (37). Thus, AC on the one hand actively attract 
phagocytes  to  secure  their  clearance  and  on  the  other  hand  prevent  the 
attraction of additional inflammatory cells.  
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3.2.2  Recognition  
 
Discrimination  between  pathogens,  necrotic  cells  (NC)  or  AC  defines  an 
important  mechanism  enabling  phagocytes  to  elicit  a  proper  immunological 
response. AC-associated molecular patterns, which are also known as ‘eat me’ 
signals, allow phagocytes to distinguish viable cells (VC) or NC from AC (8, 9). 
Bridging molecules such as thrombospondin, growth arrest-specific 6 and milk-
fat globule epidermal growth factor 8 often serve to strengthen the interaction of 
AC-associated molecular patterns and phagocyte receptors (38).  
Externalization  of  the  membrane  phospholipid  phosphatidylserine  (PS)  was 
considered a hallmark of apoptosis, as in VC, PS is mostly confined to the inner 
leaflet of the plasma membrane (39). However, in some cell types necrosis was 
also associated with PS externalization resulting in engulfment by macrophages 
and prevention of an inflammatory response (40). In general, externalization of 
PS regardless of the type of cell death might be a trigger for the clearance by 
macrophages  and  associated  with  anti-inflammatory  signaling.  Besides  PS 
receptors,  numerous  other  receptors  expressed  by  macrophages  play  an 
important  role  during  the  recognition  of  AC.  Most  of  these  receptors  are 
involved in the recognition and engulfment of pathogens or the recognition of 
oxidized  lipoproteins.  Among  these  receptors  are  integrin  receptors  (38), 
scavenger receptor CD36 (41), scavenger receptor A (42) and oxidized low-
density lipoprotein receptor 1 (43).  
In  contrast  to  ‘eat  me’  flags,  which  are  expressed  by  apoptotic  cells,  the 
expression of CD31 on the surface of VC serves as detachment or ‘don’t eat 
me’ signal via homophilic interaction with macrophage CD31 (44). Apoptosis 
provokes modification of CD31, thereby disrupting this interaction and allowing 
the phagocytosis of the respective cell.  
 
 
3.2.3  Removal  
 
After  the  interaction  of  ‘eat  me’  signals  with  phagocyte  receptors,  the 
cytoskeleton of the phagocyte is rearranged, resulting in a ‘zipper-like’ ingestion 
process.  However,  mechanistic  studies  are  obscure.  Nevertheless,  a 3 Introduction                                                                                                     12                                                                                                                                       
mechanistic  link  between  phagocytic  receptors  and  actin  filaments  was 
suggested.  Soon  after  internalization,  F-actin  is  depolymerized  from  the 
phagosome. Then, by a series of fusion and fission events with components of 
the endocytic pathway, the phagosome matures, resulting in the formation of 
the phagolysosome (45).   
 
 
3.3  Macrophage polarization  
 
Macrophages originate from myeloid progenitor cells in the bone marrow, which 
differentiate into monocytes dependent on lineage-determining cytokines such 
as GM-CSF. After the entry of monocytes into the blood stream, they can be 
allured  by  an  appropriate  stimulus  to  migrate  into  different  tissues.  There, 
monocytes differentiate into tissue macrophages under the influence of growth 
factors like GM-CSF or M-CSF. Then, the microenvironment of the respective 
tissue serves to shape the functionality of these macrophages (46, 47).   
Macrophages, as part of the body’s innate immune system, fulfill a variety of 
different  tasks.  They  represent  prodigious  phagocytic  cells,  which  efficiently 
clear  cells,  that  have  undergone  cell  death.  Their  ability  to  migrate  along 
chemokine gradients allows macrophages to intervene in inflammatory events. 
Moreover, by the presentation of endogenous and exogenous antigens and the 
secretion  of  different  cytokines,  macrophages  are  capable  of  linking  and 
shaping innate and adaptive immune responses (48).  
 
 
3.3.1  Macrophage phenotypes  
 
Macrophages show remarkable plasticity, which offers them the possibility to 
change  their  phenotype  in  response  to  environmental  signals  (49).  Thus, 
different  stimuli  polarize  macrophages  towards  various  phenotypes.  In  the 
1960s,  Mackaness  first  described  classically  activated  macrophages,  which 
arose  in  the  presence  of  microbes  (50,  51).  However,  innate  and  adaptive 
immune  responses  can  give  rise  to  a  second  type  of  macrophage,  which  is 3 Introduction                                                                                                     13                                                                                                                                       
more  susceptible  to  pathogen  infections  and  less  equipped  to  produce 
cytokines,  that  enhance  the  immune  response.  These  two  macrophage 
phenotypes were initially defined by Mantovani and co-workers as extremes of 
a continuum of functional states. Mirroring the nomenclature of Th lymphocytes, 
classically  activated  macrophages  were  denominated  as  M1  macrophages, 
while alternatively activated macrophages were termed M2 macrophages (52, 
53). Along a linear scale, M1 macrophages were classified to represent one 
extreme of macrophage activation, whereas M2 macrophages represented the 
other  extreme  (54).  While  M1  macrophages  are  associated  with  pro-
inflammatory  reactions,  pathogen  killing  and  tumor  resistance,  M2 
macrophages promote tissue remodeling and tumor formation (54).       
Classically activated macrophages arise in response to injury or infection. Th1 
lymphocyte-derived IFN-g alone or in concert with TNF-a or microbial products 
such  as  LPS  can  induce  classically  activated  macrophages,  which  results, 
among  other  parameters,  in  the  production  of  NO,  ROS  and  the  pro-
inflammatory cytokines TNF-a, IL-1 and IL-6 (54) (Figure 3).  
In  contrast,  alternatively  activated  macrophages  comprise  a  broad  range  of 
phenotypes  with  different  biochemistry  and  function.  Different 
immunomodulators such as the Th2 lymphocyte-derived cytokines IL-4, IL-13 or 
IL-10  can  provoke  polarization  towards  an  alternatively  activated  phenotype. 
Treatment  of  macrophages  with  IL-4  and  IL-13  induced  a  macrophage 
phenotype, which was characterized by the enhanced expression of IL-10 and 
arginase and was assigned as the M2a phenotype (54). Arginase contributes to 
the  production  of  the  extracellular  matrix  and  to  wound-healing  by  the 
conversion  of  arginine  to  ornithine,  which  is  a  precursor  of  polyamines  and 
collagen (55). M2b macrophages can be generated by immune complexes and 
TLR  ligands  or  IL-1  receptor  ligands.  These  macrophages  exhibit  enhanced 
secretion of TNF-a, IL-1, IL-6 and IL-10. The M2c macrophage phenotype is 
induced by IL-10, which is followed by the secretion of high levels of IL-10 and 
TGF-b  by  these  macrophages.  While  MHC  II,  which  is  needed  for  antigen 
presentation, is a feature of M1 as well as M2a and M2b macrophages, it is not 
expressed by M2c macrophages (54). 
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Figure 3. Macrophage phenotypes. Classically activated macrophages (M1 macrophages) can 
be  induced  by  IFN-g  alone  or  together  with  TNF-a  or  LPS.  This  results,  among  other 
parameters, in the production of NO, reactive oxygen speciies (ROS) and the pro-inflammatory 
cytokines  TNF-a,  IL-1  and  IL-6.  Treatment  of  macrophages  with  IL-4  and  IL-13  provokes 
polarization  towards  the  wound-healing  or  M2a  macrophage  phenotype.  This  phenotype  is 
characterized by the enhanced expression of IL-10 and arginase. Immune complexes (IC) and 
TLR ligands (TLRL) or IL-1 receptor ligands (IL-1RL) can induce the formation of a hybrid-type 
macrophage phenotype. This phenotype shows M1  as  well  as M2c characteristics and  was 
termed M2b phenotype. Among these features are the enhanced secretion of TNF-a, IL-1, IL-6 
as well as IL-10. Regulatory macrophages or M2c macrophages can be generated by immune 
complexes (IC), PG, glucocorticoids (GC), IL-10 or apoptotic cells (AC), which is followed by the 
secretion  of  IL-10  and  TGF-b.  MHC  II  is  expressed  by  all  phenotypes  except  the  M2c 
phenotype.    
 
Recently, three functional states of macrophage activation were proposed for 
classification as an alternative for the M1/M2 pattern, which are host defense, 
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macrophage phenotypes, denoted classically activated macrophages, wound-
healing macrophages and regulatory macrophages, were illustrated as the three 
primary colors in a color wheel. This model is useful for the classification of 
macrophages, which exhibit characteristics that are shared by more than one 
macrophage  population,  as  these  macrophages  are  illustrated  analogous  to 
secondary  colors  in  the  color  spectrum,  finally  resulting  in  ‘hybrid-type’ 
macrophages  (56).  Thus,  this  classification  reflects  the  high  plasticity  in 
macrophage  responses,  which  is  why  I  prefer  to  use  this  classification. 
Therefore, in the following I will distinguish classically activated macrophages 
from  wound-healing  macrophages,  regulatory  macrophages  and  hybrid-type 
macrophages. 
 
 
3.3.2  Macrophage polarization by apoptotic cells      
 
AC modulate the functional response of macrophages apart from simply being 
removed and thus shape their phenotype.  
 
3.3.2.1   Attenuation of pro-inflammatory responses 
Notably,  phagocytosis  of  AC,  in  contrast  to  pathogen  phagocytosis,  is 
associated  with  an  active  anti-inflammatory  response.  This  response  is 
characterized by an attenuated release of pro-inflammatory mediators and an 
increase in the secretion of anti-inflammatory mediators.  
Following co-culture with apoptotic lymphocytes, LPS-induced TNF-a and IL-1b 
expression  in  monocytes  was  attenuated,  whereas  IL-10  expression  was 
enhanced (57). This finding was supported by many others, showing that AC 
provide  signals  to  directly  influence  macrophages,  i.e.  to  repress  their  pro-
inflammatory response (Figure 4). The autocrine signaling of TGF-b, PGE2 or 
platelet  activating  factor,  all  of  which  are  secreted  from  macrophages  in 
response  to  AC,  plays  a  central  role  in  the  inhibition  of  pro-inflammatory 
cytokine expression (58). These factors were reported to be responsible for the 
reduction of IL-1b, IL-8 as well as TNF-a after co-incubation periods of more 
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Figure  4.  Macrophage  polarization  by  apoptotic  cells.  Apoptotic  cells  (AC)  polarize 
macrophages (MF) by the secretion of soluble factors and/or via cell-cell contact-dependent 
mechanisms.  The  most  prominent  pathways  involve  induction  of  cyclooxygenase  (COX)-2 
expression,  which  was  suggested  to  enhance  IL-10  levels.  The  activation  of  peroxisome 
proliferator-activated  receptor  (PPAR)-g  inhibits  LPS-induced  NF-kB  signaling,  further 
contributing to shift the balance between pro-inflammatory (Pro-infl) and anti-inflammatory (Anti-
infl) mediators towards the anti-inflammatory ones. Furthermore, PPAR-g also inhibits NADPH 
oxidase and thus the production of reactive oxygen species. Besides providing protection of 
macrophages  against  apoptosis,  AC  also  induce  arginase  expression,  which  results  in  the 
inhibition of inducible NO synthase (iNOS)-associated NO production.   
 
NF-kB  forms  a  major  transcriptional  regulator  of  pro-inflammatory  cytokine 
expression  (59).  LPS-induced  NF-kB  activation  was  demonstrated  to  be 
impaired  by  AC,  although  NF-kB  binding  to  DNA  as  well  as  inhibitor  of  kB 
degradation were not affected by AC implying the involvement of co-activators 
and/or co-repressors (60). Recently, mechanistic details were provided by the 
observation  that  AC  induce  small  ubiquitin-like  modifier  (SUMO)ylation  of 
peroxisome  proliferator-activated  receptor  (PPAR)-g,  which  prevents  LPS-
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promoters  of  pro-inflammatory  cytokines  (61).  However,  at  present  the 
receptors and molecular pathways initiating PPAR-g SUMOylation remain to be 
identified.    
Even though alternative macrophage activation after interaction with apoptotic 
cells  was  observed  by  a  multitude  of  reports,  the  type  of  macrophage/AC 
interaction as well as the underlying molecular signaling circuits are ill defined. 
Several reports showed an involvement of PS, Mer tyrosin kinase receptor and 
vitronectin receptor in immunosuppression, although phagocytosis per se was 
not  essential  (62).  However,  generalized  effects  and  details  are  still 
controversial.  
 
 
3.3.2.2   Attenuation of ROS and NO formation 
The bactericidal capacity of macrophages is partly defined by the generation of 
NO  (63)  and  ROS  (64).  Treatment  of  macrophages  with  LPS  and/or  IFN-g 
initiates the upregulation of inducible NO synthase (iNOS), which catalyzes the 
oxidation  of  L-arginine  to  L-citrulline  and  NO  (65).  Several  reports  showed 
reduced NO levels in response to AC (66, 67). Arginase seems to play a crucial 
role  in  this  process,  as  it  metabolizes  L-arginine  to  urea  and  ornithine,  thus 
competing  with  iNOS  for  the  same  substrate  (68).  On  the  one  hand,  it  was 
reported  that  AC  induce  arginase  1  expression  in  a  PS-dependent  manner, 
while simultaneously attenuating iNOS expression (69). On the other hand, it 
was shown that arginase 2 was upregulated by AC (70). However, arginase 2 
expression  was  cell-cell-contact-independent.  Instead  soluble  factors,  which 
were  secreted  by  AC,  were  suggested  to  mediate  arginase  2  induction. 
Interestingly, in this report iNOS expression was unaffected. 
ROS  are  generated  during  the  oxidative  burst,  which  is  initiated  by  protein 
kinase-dependent assembly of the NADPH oxidase complex (71). Attenuated 
ROS formation, which was observed after interaction of macrophages with AC, 
was proposed to be attributed to a cell-cell-contact-dependent mechanism (72). 
This  mechanism  was  suggested  to  involve  PPAR-g,  although  mechanistic 
details are still unknown (73). Taking into consideration that PPAR-g also plays 
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cytokines,  PPAR-g  can  be  considered  as  an  eminent  factor  shaping  the 
phenotype of regulatory macrophages.  
 
 
3.3.2.3   S1P and IL-10 in macrophage polarization    
As mentioned before, not only recognition-dependent signals, but also soluble 
factors released by AC were proven to induce macrophage polarization. Among 
these factors S1P and IL-10 play an important role. 
Co-culture  of  tumor  cells  with  primary  human  macrophages  resulted  in 
apoptosis  induction  in  tumor  cells  and  alternative  activation  of  macrophages 
(74).  Apoptosis  induction  was  essential  for  the  induction  of  the  alternative 
macrophage phenotype, whereas conditioned medium from AC also polarized 
macrophages,  which  argued  for  a  soluble  factor.  S1P  was  identified  as  the 
crucial  factor,  which  is  secreted  from  AC  and  provides  protection  of 
macrophages  against  apoptosis  (35).  Moreover,  AC-derived  S1P  was 
suggested  to  reduce  TNF-a  and  IL-12p70  secretion  and  to  enhance  the 
expression of IL-8 and IL-10 (74).   
IL-10 is also produced by AC (75) and has emerged as a key regulator for the 
suppression  of Th1  responses  (76),  since the  IL-10-induced  DNA  binding  of 
STAT3  homodimers  is  followed  by  the  attenuation  of  transcription  of  pro-
inflammatory mediators (77). Cyclooxygenase (COX)-2 seems to be involved in 
increasing  IL-10  levels.  COX-2  constitutes  the  rate-limiting  enzyme  in  the 
conversion of arachidonate to PGH2, which can be further metabolized towards 
anti-inflammatory  mediators  such  as  the  PPAR-g  agonist  15d-PGJ2  (78,  79). 
COX-2 expression in macrophages due to interaction with AC was shown to be 
either facilitated via a cell-cell-contact-dependent mechanism (66) or via AC-
derived  S1P  (80).  Increased  PGE2  production  has  been  linked  to  impaired 
pathogen clearance by  lung alveolar macrophages and to elevated levels of 
IL-10,  which  were  dependent  on  E  prostanoid  receptor  2-induced  cAMP 
generation  (81).  cAMP  signaling  is  considered  a  hallmark  of  regulatory 
macrophages  in  the  resolution  phase  of  inflammation  and  is  generally 
accompanied by COX-2 expression and the secretion of high levels of IL-10 
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3.4  Sphingosine-1-phosphate 
 
The  bioactive  lipid  mediator  S1P  is  derived  from  plasma  membrane 
sphingolipids (83). S1P was originally considered to be just an inert structural 
component of the cell membrane (84). However, today the important role of 
S1P as  a  signaling  molecule  in  a  plethora of  biological  processes,  including 
Ca
2+ mobilization, cell growth, survival and cell motility, has become clear (85).  
 
 
3.4.1  S1P metabolism 
 
Cellular  S1P  levels  are  low  and  tightly  regulated  by  the  balance  between 
synthesis and degradation (86). Ceramide constitutes an important progenitor in 
the synthesis of S1P. The crucial step in the de novo synthesis of ceramide 
occurs by condensation of serine and palmitoyl-CoA to form 3-ketosphinganine 
(Figure  5).  Followed  by  multiple  catalytical  steps,  3-ketosphinganine  is 
converted  into  ceramide.  The  second  way  of  ceramide  production  is  the 
hydrolysis of membrane sphingomyelin by sphingomyelinase, a reaction, which 
can  be  reversed  by  sphingomyelin  synthase.  Ceramide  is  subsequently 
deacylated by ceramidase to sphingosine. Sphingosine can be reconverted to 
ceramide  by  ceramide  synthase.  Finally,  phosphorylation  of  sphingosine  by 
sphingosine kinase (SphK) results in S1P generation. The turnover of S1P is 
mediated  via  two  different  pathways.  S1P  can  either  be  reversibly 
dephosphorylated to sphingosine by specific S1P phosphohydrolase or it can 
be  irreversibly  cleaved  by  S1P  lyase  to  form  phosphoethanolamine  and 
hexadecenal (87, 88).  
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Figure 5. Synthesis and action of S1P. Sphingosine-1-phosphate (S1P) can be synthesized de 
novo by condensation of serine and palmitoyl-CoA or by sphingomyelinase (SMase)-mediated 
hydrolysis of sphingomyelin to ceramide. Ceramide can either be reconverted to sphingomyelin 
by sphingomyelin synthase (SMsyn)  or it can  be converted  into sphingosine by  ceramidase 
(CDase).  The  latter  reaction  can  be  reversed  by  ceramide  synthase  (CDSyn).  Sphingosine 
kinase (SphK) catalyzes the phosphorylation of sphingosine to S1P. S1P degradation can either 
be mediated by dephosphorylation by S1P phosphohydrolase (SPP) or by irreversible cleavage 
catalyzed by S1P lyase. After the export of S1P via ATP binding cassette (ABC) transporter 
S1P can occupy five specific S1P receptors (S1P1-5). Ligation of S1P receptors can result in the 
activation of a various cellular signaling pathways, which are activated directly or via G-proteins 
(Gq, Gi, G12/13). These pathways include phospholipase C (PLC), Rac, p38 MAPK (p38), ERK, 
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3.4.2  Sphingosine kinases 
 
S1P is generated by phosphorylation of sphingosine by sphingosine kinases, an 
enzyme family consisting of two isoenzymes, namely SphK1 and SphK2. SphKs 
exhibit different kinetic properties and substrate specificities and they differ in 
their temporal expression patterns during development as well as in their tissue 
distribution (86, 89). Moreover, at the cellular level SphK isoforms may fulfill 
distinct  or  even  antithetic  biological  virtues,  although  facilitating  the  same 
reaction (90).   
SphKs  constitute  evolutionary  conserved  enzymes.  They  were  proven  in 
humans as well as in mice, yeast and plants, having also homologs in worms 
and flies (86). In humans, alternative splice variants for both isoenzymes have 
been described (87).  
SphKs  are  regulated  on  transcriptional  level  and  also  via  posttranslational 
modifications.  After  treatment  with  platelet-derived  growth  factor  (PDGF)  or 
cytokines such as TGF-b (91)  and IL-1 (92) or under hypoxia (93), enhanced 
mRNA  levels  of  SphK1  were  detected.  The  induction  of  SphK  activity  was 
shown to be predominantly regulated by growth factors like epidermal growth 
factor, nerve growth factor and PDGF. Moreover, SphK activity, among others, 
is also stimulated by G protein-coupled (GPC) receptor agonists, cross-linking 
of immunoglobulin receptors, TNF-a and even S1P itself (88). 
The activity of SphK1 has been associated with enhanced growth, proliferation 
and protection against apoptosis in a multitude of cellular systems (86). In the 
following,  I  will  focus  on  the  regulation  of  apoptosis,  as  in  this  aspect  the 
opposing roles of the two SphK isoforms appear most prominent.  As SphK1 
has  a  substantial  basal  activity  and  stimulation  with  agonists  often  provokes 
only a slight increase in catalytic activity, it was suggested that translocation to 
subcellular compartments might be the important step in SphK1 regulation (89).  
Phosphorylation of SphK1 by ERK was shown to result in increased activity of 
SphK1, which was accompanied by its translocation from cytosol towards the 
plasma  membrane,  where  it  phosphorylated  sphingosine  to  S1P  (94).  After 
externalization of S1P, it can occupy its receptors, a process which is called 
‘inside-out’ signaling (86). However, during apoptosis SphK1 can be cleaved, 
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On the contrary, SphK2 promotes apoptosis when being overexpressed. This 
pro-apoptotic property can be attributed to its N-terminal BH3 domain, which 
allows the physically interaction of SphK2 with Bcl-XL, an anti-apoptotic Bcl-2 
family  protein,  causing  its  inactivation  and  thus  induction  of  apoptosis  (96). 
Nevertheless, disruption of this interaction only partly reduced the apoptosis-
inducing  capability  of  SphK2.  This  raised  the  proposal  that  SphK2  and  S1P 
phosphohydrolase act in concert with ceramide synthase at the endoplasmic 
reticulum  (ER)  to  convert  S1P  to  sphingosine,  and  subsequently  to  pro-
apoptotic  ceramide.  Thus,  the  subcellular  localization  of  S1P  formation  may 
define  its  impact  on  apoptosis.  Furthermore,  SphK2  overexpression  was 
reported  to  suppress  cell  growth  via  its  nuclear  localization  which  was 
accompanied by inhibition of DNA synthesis (97). Interestingly, S1P, which was 
generated by AC and protected macrophages against apoptosis, was mainly 
derived from SphK2 (35).  
Genetic  deletion  of  both,  SphK1  and  SphK2  together,  in  mice  resulted  in 
prenatal death (98) as a consequence of severely disturbed neurogenesis and 
angiogenesis,  which  reinforces  the  regulatory  impact  of  S1P  on  several 
complex  biological  circuits  such  as  survival,  proliferation  or  migration  (86). 
Interestingly, deletion of either SphK1 or SphK2 alone was not associated with 
an obvious phenotype under unstressed conditions, indicating that SphKs may 
compensate for each other (98). 
 
 
3.4.3  S1P as a signaling molecule    
 
In mammals, S1P is enriched only in the blood and lymph (99). In the plasma, 
S1P  is  mainly  bound  to  high-density  lipoprotein  or  albumin  and  can  reach 
micromolar  concentrations  (99,  100).  Tissue  levels  of  S1P  are  not  easy  to 
determine without causing tissue cell stress or tissue disruption (100). However, 
they are believed to be below the amount necessary for receptor activation, 
although all cells synthesize S1P in association with the turnover of membrane 
sphingolipids through the endocytic recycling pathway (86). This indicates that 
S1P secretion could be performed by specialized cells such as erythrocytes, 
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S1P to the lymph and/or plasma (102). However, the low tissue levels of S1P 
could also be a consequence of enhanced S1P degradation.   
Most of the S1P-dependent modulations of immune responses are attributed to 
S1P  receptor  ligation.  Upon  its  generation by  SphK from  plasma  membrane 
sphingolipids,  S1P  can  either  engage  S1P  receptors  in  an  auto-  and/or 
paracrine fashion or can act as a second messenger with intracellular activity, 
which  was  originally  suggested  to  be  the  task  of  S1P  (103,  104).  A  direct 
intracellular target for S1P had for a long time not been identified. Nevertheless, 
several studies described intracellular S1P actions that were not imitated by 
extracellular S1P and could not be attributed to coupling to S1P receptors (89). 
Intracellular  S1P  could  simply  shift  the  balance  between  pro-apoptotic 
ceramid/sphingosine  and  anti-apoptotic  S1P,  the  so-called  ‘sphingolipid 
rheostat’, towards S1P and survival (86). Furthermore, activation of SphK was 
reported to mediate intracellular signaling via MAPK (105) or calcium currents 
(106). According to this observation, TNF-a activated SphK1 resulting in NF-kB 
activation  and  protection  against  apoptosis  (107).  However,  recently  the 
molecular  mechanism  of  the  action  of  intracellular  S1P  was  revealed.  S1P 
generated  by  SphK2  was  shown  to  inhibit  histone  deacetylases  resulting  in 
enhanced expression of the cyclin-dependent kinase inhibitor p21 (108). 
Coupling of S1P to its specific receptors is important for directed cell movement, 
angiogenesis,  vascular  maturation  and  immunity  (86).  However,  mechanistic 
details revealing how S1P is released from cells to occupy its specific receptors 
are limited. In mast cells and platelets, which store S1P, its release is facilitated 
by ATP binding cassette family transporters (109, 110). Alternatively, in human 
endothelial cells a splice variant of SphK1 was reported to be exported from the 
cells,  provoking  extracellular  production  of  S1P  (102).  Furthermore,  it  was 
hypothesized that S1P could also be flipped from the inner leaflet to the outer 
leaflet of the plasma membrane (99).  
Over  the  last  years  it  became  apparent  that  the  SphK,  S1P,  S1P  receptor 
signaling axis in macrophages might play a central role in the pathogenesis of 
inflammatory diseases such as atherosclerosis, rheumatoid arthritis, asthma as 
well as cancer (111). 
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3.4.4  Sphingosine-1-phosphate receptors     
 
S1P  receptors  belong  to  the  family  of  hepta-helical  GPC  transmembrane 
receptors. In vertebrates, five isoforms of S1P receptors termed S1P1-5 have 
been identified. S1P receptors differ in their association with different G-proteins 
and also in their binding affinity for S1P, which is in the nanomolar range. In 
general, activation of S1P receptors is followed by different G-protein cascades 
in  which,  among  others,  the  activation  of  phospholipase  C,  PI3K,  adenylyl 
cyclase, ERK 1/2, p38 MAPK and JNK are involved. Although S1P receptors 
activate common GPC pathways, they are only partly redundant in their cellular 
signaling capacity (99, 112). Thus, the S1P receptor expression profile on the 
respective cells represents a critical parameter determining the influence of S1P 
on distinct cell populations. 
While S1P1-3 have a wide tissue distribution, S1P4 is predominantly expressed 
in lymphoid tissue and platelets and S1P5 is restricted to the nervous system, 
NK cells and some dendritic cells (84, 113, 114). In mononuclear cells, species-
dependent  alterations  in  the  S1P  receptor  expression  profile  were  detected. 
While human monocytes express S1P1, S1P2 and S1P4, human macrophages 
express S1P1-4 (115), whereas murine macrophages are restricted to S1P1 and 
S1P2 (116).  
S1P receptor gene deletion studies underlined the importance of S1P receptors. 
S1P1 single and S1P2/3 double knockout mice died in utero as a consequence 
of  severe  developmental  vascular  defects,  which  were  similar  to  the  picture 
seen in SphK1/2 knockout mice (117).   
The  activation  of  S1P  receptor  signaling  is  a  transient  process.  In  S1P1 
overexpressing human embryonic kidney cells exogenous S1P treatment, in a 
dose-dependent manner, induced receptor translocation to perinuclear vesicles 
(118). S1P1 was suggested to be phosphorylated at its C-terminal tail, which is 
followed by the recruitment of the adapter protein arrestin and the induction of 
receptor internalization via clathrin coated pits. However, S1P1 recycled back to 
the plasma membrane. Thus, S1P specifically induces the reversible trafficking 
of S1P1 via the endosomal pathway. 
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3.4.5  The important role of S1P1 during trafficking of immune cells   
 
S1P1 receptor mRNA was originally isolated from human endothelial cells as an 
immediate-early gene product which was induced by phorbol 12-myristate 13-
acetate (119). In vascular cells, S1P1 was shown to be upregulated following 
treatment with growth factors such as vascular endothelial growth factor (VEGF) 
or basic fibroblast growth factor (120, 121). However, the pathways mediating 
S1P1 induction remain to be determined. The only transcription factor, that has 
been described to provide S1P1 induction is krüppel-like factor (KLF), a member 
of the zinc finger family of transcription factors, which plays diverse roles during 
differentiation and development (122, 123).  
The  vascular  S1P  gradient,  i.e.  S1P  is  enriched  in  the  circulatory  system, 
whereas it is estimated to be much lower in interstitial fluids of tissues, is a 
spatial cue for lymphocyte and hematopoietic cell trafficking (99). In the lymph, 
S1P was suggested to serve as a chemoattractant to allow lymphocyte egress 
from  the  thymus,  secondary  lymphoid  organs  and  Peyer’s  patches  (99). 
Furthermore, B cell recruitment from the bone marrow to the periphery, dendritic 
cell  trafficking  from  the  periphery  to  the  lymph  nodes  and  hematopoietic 
progenitor cell recirculation are regulated by S1P (99). Lymphocyte S1P1 levels 
are  downregulated  during  transit  through  the  blood,  upregulated in  lymphoid 
organs, and downregulated again in the lymph (124).  
The expression of S1P1 is critical for T cell egress from the thymus and homing 
to the lymph nodes (Figure 6). T cells must complete negative selection before 
they can leave the thymus and they aquire the ability to migrate towards S1P 
only  at  the  mature  single-positive  stage  (100).  Following  the  entry  of  naïve 
lymphocytes  into  a  secondary  lymphoid  organ from the  blood, they  travel  to 
separate subcompartments where they survey for antigen. In the absence of 
antigen  encounter,  lymphocytes  leave  the  respective  organ  via  the  efferent 
lymphatics or in the case of the spleen, via the red pulp (124). However, in an 
inflamed  lympoid  organ  S1P1  is  internalized.  After  activation  by  TCR 
stimulation,  T  cells  downregulate  S1P1  mRNA,  thus  loosing  their  ability  to 
migrate towards S1P. Three days after activation, S1P1 mRNA starts to recover, 
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Figure  6.  Role  of  S1P  receptor  1  during  T  lymphocyte  trafficking.  Mature  single-positive  T 
lymphocytes express S1P receptor 1 (S1P1) on their surface, which enables them to migrate 
into the blood along S1P gradients. There, due to high S1P concentartions S1P1 is internalized. 
Following entry of naïve T cells into secondary lymphoid organs they survey for antigens, while 
S1P1 reappears on the cell surface. In the absence of antigens T cells leave the secondary 
lymphoid  organ  and  enter  the  blood  again.  However,  when  T  cells  arrive  in  an  inflamed 
lymphoid  organ  S1P1  is  internalized  and  S1P1  transcription  decreases  in  response  to  an 
activating TCR signal. After three days S1P1 is expressed on T cell surface again, allowing the 
newly generated effector T cells to enter the blood.  
 
 
3.5  Heme oxygenase   
 
Heme  (iron-protoporphyrin  IX)  constitutes  an  essential  molecule  for  all 
nucleated cells, as it senses or uses oxygen (125). It functions as a prosthetic 
moiety of various hemoproteins including hemoglobin, myoglobin, cytochromes, 
COX, NOS and soluble guanylyl cyclase (126). As heme cannot be recycled 
among different cells, it must be synthesized and degraded within an individual 
cell. An exception to this rule is formed by senescent erythrocytes, which are 
phagocytosed  by  macrophages  in  the  reticuloendothelial  system,  in  which 
hemoglobin  is  separated  to  the  heme  and  globin  moieties.  While  the  globin 
moiety is hydrolyzed to amino acids, heme breakdown is catalyzed by heme 
oxygenase. (125). Hemoglobin derived from senescent erythrocytes forms the 
major source of heme for macrophages (125), although it was postulated that 
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Heme oxygenase (HO) was discovered in 1968 as a microsomal enzyme, which 
catalyzes the initial and rate-limiting step in the oxidative degradation of heme 
to  equimolar  quantities  of  biliverdin  IXa,  Fe
2+  and  carbon  monoxide  (CO) 
(Figure  7)  (128,  129).  In  mammals,  HO  forms  complexes  with 
NADPH: cytochrome  P-450  reductase,  which  provides  reducing  equivalents 
required for the catalytic turnover as well as with NAD(P)H: biliverdin reductase, 
which catalyzes the further metabolization of biliverdin to bilirubin (130, 131). 
Bilirubin is transported to the liver, where it is conjugated with glucuronic acid 
and excreted into bile. Fe
2+ can be used for heme synthesis in the cell or it can 
be transported via transferrin to other tissues, mainly the bone marrow. CO is 
transported to the lung, where it is exhaled (125, 132).  
 
 
 
Figure 7. The pathway of heme metabolism. Using the reducing capacity of NADPH, which is 
delivered by NADPH:cytochrome P-450 reductase, heme oxygenase (HO) catalyzes the rate-
limiting step in the oxidative degradation of heme to equimolar quantities of biliverdin IXa, Fe
2+ 
and carbon monoxide (CO). Biliverdin-IXa is further metabolized to bilirubin IXa by biliverdin 
IXa reductase under the use of NADPH.  
 
 
3.5.1  Tissue distribution of HO    
 
In recent years, three isoforms of HO have been described. HO-1 and HO-2 are 
the  products  of  distinct  genes  (133).  However,  as  stop  codons  are  present 
within the coding region of the HO-3 gene and a lack of detectable mRNA or 
protein  product  was  observed  in  rat  tissues,  HO-3  was  considered  to  be  a 
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HO-1 constitutes an inducible enzyme, which is expressed ubiquitously at low 
levels, whereas HO-2 is constitutively expressed (135). HO-1 is found in high 
amounts  in  liver,  spleen  and  bone-marrow,  where  relatively  high  heme 
concentrations due to continuous erythrocyte turnover are present (135). Large 
amounts of HO-2 were found in the brain, testes and endothelial cells (136). 
Interestingly,  in  the  rat  brain  HO-2  was  shown  to  co-localize  with  soluble 
guanylyl cyclase, suggesting a role for CO in neurotransmission through the 
cGMP pathway (137). Furthermore, the high expression of HO-2 in endothelial 
cells  points  to  a  role  of  CO  in  vasorelaxation,  as  exogenously  applied  CO 
lowered blood pressure in spontaneously hypertensive rats (138).  Moreover, a 
role for HO-2 as an oxygen sensor for calcium-sensitive potassium channels in 
carotid cells was also reported (139). 
The  focus  of  my  work  was  the  inducible  isoform  HO-1,  which  plays  a 
cytoprotective  role  by  modulating  tissue  response  to  injuries  in  various 
pathological states (140). 
 
 
3.5.2  Subcellular localization of HO-1  
 
HO-1 was originally reported to localize to the smooth ER (141). It is embedded 
in the ER membrane with an insertion sequence near its C-terminal portion, 
while  a  large  domain  containing  the  N-terminus  is  exposed  cytoplasmically 
(142). 
However, HO-1 was also demonstrated to localize to the mitochondria (143). 
Furthermore, among other stimuli, hemin was shown to provoke translocation of 
HO-1 into the nucleus (144). Nuclear entry was facilitated by protease-mediated 
C-terminal  cleavage  and  was  also  associated  with  reduction  of  HO  activity. 
Nevertheless,  nuclear  and  cytoplasmic  HO-1  similarly  provided  protection  of 
cells against hydrogen peroxide-mediated injury. Thus, nuclear localization of 
HO-1  was  suggested  to  serve  for  upregulation  of  genes  that  promote 
cytoprotection against oxidative stress. HO-1 was reported to activate oxidant 
responsive  transcription  factors  including  AP-1,  although  mechanistic  details 
were not provided. As the structure of HO-1 contains no traditional DNA binding 
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or a protein complex was suggested. Another study showed that the interaction 
of HO-1 with caveolin-1 in the plasma membrane of rat endothelial cells also 
decreased the enzymatic activity of HO-1 (145). Recently, it was demonstrated 
that HO-1 forms dimers/oligomers in the ER (146). Truncation of the C-terminal 
transmembrane segment provoked translocation of HO-1 into the cytosol and 
nucleus  indicating  that  the  transmembrane  segment  is  crucial  for  the 
stabilization of HO-1 in the ER.  
 
 
3.5.3  Regulation of HO-1  
 
The  original  characterization  of  HO-1  as  an  inducible  enzyme  by  non-heme 
agents  involved  the  use  of  heavy  metals  (147).  Besides  their  potential  to 
increase HO-1 activity, heavy metal ions can enhance the de novo synthesis of 
HO-1 (148). Today, a broad spectrum of inducers of HO-1 has been identified, 
including various noxious stressors, such as ROS (149), NO (150), LPS (151), 
ultraviolet (UV) radiation (149) as well as its physiological substrate heme (152).   
HO-1 is regulated primarily at the level of gene transcription (153). However, 
hypoxia  was  reported  to  regulate  HO-1  gene  expression  by  stabilization  of 
mRNA,  although  hypoxia  also  induces  HO-1  protein  expression  through  p38 
MAPK  and  PKC  (154,  155).  Furthermore,  the  involvement  of  translational 
control of HO-1 expression by cobalt ions has been suggested (148). Besides 
its  role  in  regulating  HO-1  expression  at  the  transcriptional  level,  Akt/PKB 
mediates  posttranslational  phosphorylation  of  HO-1  at  its  serine-188  residue 
and thus enhances its activity (156).  
The  diversity  of  HO-1  inducers  is  reflected  by  the  variety  of  pathways  and 
transcription factors, which  are  involved  in  HO-1  gene  regulation.  HO-1  is  a 
representative  phase  II  detoxification  enzyme,  whose  stress-responsive 
element  is  structurally  and  functionally  similar  to  the  antioxidant  responsive 
element (135, 157). As the redox-sensitive transcription factor NF E2-related 
factor-2 (Nrf2) plays a major role in the transcriptional activation of ARE-driven 
genes (158, 159), current research indicates that Nrf2, besides various other 
transcription  factors  with  minor  roles,  is  a  critical  regulator  of  HO-1  gene 
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The  fact  that  HO-1  can  also  be  induced  by  quaint  stimuli  such  as  cigarette 
smoke  (160),  diesel  exhaust  particles  (161)  and  broccoli  extracts  (162) 
confronts us with HO-1 ever during our whole life. Importantly, the medicinal 
effects of pharmaceutical compounds such as aspirin (163) and statins (164) 
may be imparted indirectly through HO-1 induction, which then mediates their 
therapeutic effects.    
 
 
3.5.4  Cytoprotective effects of HO-1  
 
As HO-1 is induced by various oxidative stressors, the assumption was raised 
that the induction of HO-1 is associated with protection of cells against these 
insults and thus with the limitation of tissue damage (165). In fact, in several 
disease models, including cardiac ischemia and reperfusion injury as well as 
pulmonary inflammation, hypertension and sepsis, the expression of HO-1 was 
shown to be potently cytoprotective (166, 167). Thus, the induction of HO-1 can 
be regarded as an adaptive response, i.e. inducible defense, to several injurious 
stimuli.  Besides  its  anti-oxidative  role,  anti-inflammatory  as  well  as  anti-
proliferative  and  anti-apoptotic  properties  have  also  been  attributed  to  HO-1 
(166).  
An interesting research field has opened to the scientific community, as it was 
discovered that the by-products of heme degradation are not just obscure waste 
products  with  potential  toxicological  implications,  but  can  also  be  associated 
with numerous biological functions (135). Thus, the interest in HO enzymes has 
shifted from their well-defined metabolic function of heme catabolism to their 
potential  cytoprotective fuction  in  different models  of  cellular  stress  or  organ 
pathology. 
The  products  of  heme  degradation  were  shown  to  mimic  the  cytoprotective 
effects, which were ascribed to HO-1 involving a plethora of different disease 
models and pathways (166). In the following, I will focus on the cytoprotective 
effects, which are directly associated with heme turnover.   
One key effect is the degradation of the potentially dangerous intracellular pro-
oxidant  heme  by  HO-1,  which  was  the  initial  explanation  for  the  numerous 
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radical  scavenger  and  was  considered  as  an  important  antioxidant  molecule 
(169). Furthermore, bilirubin can also counteract nitrosative reactions (170). As 
an indirect effect, the generation of Fe
2+ is balanced by a strong induction of the 
synthesis of ferritin, an iron-sequestering protein (171). Thus, participation of 
free  iron  in  the  so-called  ‘Fenton  reaction’,  which  generates  highly  reactive 
hydroxyl radicals from hydrogen peroxide, might be limited (172). Furthermore, 
an  ATPase  is  co-localized  in  the  ER  with  HO-1  and  transports  Fe
2+  to  the 
luminal side of the ER. It was suggested that within the lumen of the ER Fe
2+ 
may be oxidized to Fe
3+, bind transferrin and return to the extracellular fluid via 
the exocytotic pathway (173).   
Although functional roles for the other heme degradation products have been 
reported, CO has received increasing attention (174). CO was first considerd as 
an inert gaseous molecule with little physiological relevance (175). It was rather 
associated  with  lethality,  as  it  bears  a  high  affinity  for  hemoglobin,  which  is 
approximately  245  times  that  of  oxygen  in  humans  (176),  thus  preventing 
oxygen  delivery  to  tissues  and  organs  and  creating  tissue  hypoxia  (166). 
Furthermore, CO can act as a neurotoxin poisoning the respiratory chain in the 
mitochondria, thereby suppressing aerobic glycolysis (177). However, according 
to the statement of Paracelsus that ‘the right dose differentiates a poison from a 
remedy’  (176)  it  was  shown  that  in  macrophages  CO  suppresses  the 
expression  of  the  LPS-induced  pro-inflammatory  cytokines  TNF-a,  IL-1b  and 
macrophage  inflammatory  protein-1b,  while  increasing  the  LPS-induced 
expression  of  the  anti-inflammatory  cytokine  IL-10  (167).  Furthermore,  CO 
inhibits platelet aggregation, which might be accompanied by the suppression of 
thrombosis  and  the  pro-inflammatory  damage  induced  by  activated  platelets 
(178). Other effects elicited by CO include prevention of apoptosis in several 
types  of  cells,  such  as  endothelial  cells,  fibroblasts  and  macrophages  (179-
181). Furthermore, CO exerts potent anti-proliferative effects on cells, including 
T lymphocytes and airway smooth muscle cells (182, 183). It was shown that 
predominantly cGMP and p38 MAPK play a role in mediating the cytoprotective 
effects of CO (158). However, mechanistic details are still elusive.    
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3.5.5  Involvement of HO in diseases 
 
A single case report described a patient diagnosed with genetic deficiency of 
the  HO-1  gene,  who  exhibited  serious  impairment  of  iron  metabolism.  The 
phenotype was accompanied by severe persistent leukocytosis and increased 
vulnerability  to  oxidant  injury  besides  growth  retardation  and  anemia.  The 
patient eventually died of intracranial hemorrhage at the age of six years (184, 
185).   
HO-1-deficient mice exhibit a similar phenotype compared to this patient, which 
underscores the importance of HO-1 in cellular homeostasis (186). As VEGF 
synthesis was shown to be partially dependent on HO-1, it was suggested that 
the  embryonic  lethality  of  HO-1  knockout  mice  may  involve  defects  in 
angiogenesis or vasculogenesis (187). Furthermore, it was also hypothesized 
that impairment of angiogenesis, required for proper ovulation and male fertility, 
could play a role in reducing the fertility of HO-1 knockout mice (187).   
HO-1 is upregulated in a multitude of tumors including human prostate cancer 
and squamous carcinoma (136). Interestingly, in different forms of cancer such 
as human melanoma, HO-1  was specifically expressed in macrophages, but 
only slightly in tumor cells (188). Unfortunately, HO-1 expression in cancer cells 
can  be  further  increased  in  response  to  chemotherapy,  radiation  or 
photodynamic  therapy  (189,  190)  and  then  may  offer  cancer  cells  a  growth 
advantage.  
To date, three polymorphisms in the 5’-flanking region of the HO-1 gene have 
been discovered in humans, a (GT)n dinucleotide repeat polymorphism and two 
single  nucleotide  polymorphisms,  G(-1135)A  and  T(-413)A  (191).  The  (GT)n 
polymorphism was suggested to influence the basal promoter activity as well as 
the induction level of the HO-1 gene expression in response to stress. This was 
supposed  to  be  attributed  to  Z-DNA,  left-handed  helices,  which  long  (GT)n 
repeats are likely to form, and which may reduce the transcription of the HO-1 
promoter  (125).  Indeed,  in  vitro,  short  HO-1  alleles  (<25  GT  repeats)  show 
stronger promoter activity following treatment with H2O2, compared to longer 
alleles (192). Interestingly, in most cases long (GT)n repeats are associated with 
susceptibility to pathological conditions such as the presence of emphysema in 
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revealed that the homozygous short allele was found more frequently in the 
melanoma  group  (192).  However,  the  short  HO-1  allele  also  conveyed 
protection against various disease entities such as restenosis as well as local 
vascular  inflammation  following  percutaneous  transluminal  angioplasty  (194, 
195). Thus, the increased HO-1 expression associated with short HO-1 alleles 
on the one hand might provide protection of tumor cells against apoptosis but 
on  the  other  hand  exhibits  potent beneficial  roles  in a  vast number  of  other 
pathologies. While the G(-1135)A polymorphism has not been reported to cause 
any pathologies, the T(-413)A polymorphism was involved in coronary artery 
disease as well as hypertension in women (191).  
Targeting HO-1 has been proven to be potently cytoprotective in ameliorating 
the  pathology  associated  with  a  plethora  of  disease  processes.  Tin-
protoporphyrin, a potent competitive inhibitor of HO-1, has been successfully 
used for the treatment of hyperbilirubinemia in newborn rats (196). Furthermore, 
the administration of biliverdin and/or bilirubin in rodent models was shown to 
elicit protection in several disease states including ischemia/reperfusion injury, 
transplant rejection and inflammatory bowel disease (176). CO also coveyed 
protection  in  several  rodent  disease  models  including  sepsis,  different  lung 
injury models, ischemia/reperfusion injury and organ transplantation (135). The 
exogenous  administration  of  CO  and/or  biliverdin  and  bilirubin  appears 
promising in treating human diseases. However, standard clinical phase trials 
are required to determine efficacy, toxicological profiling, tissue distribution and 
half-life of these agents (176). 
 
 
3.6  Aims of this study    
 
The objective of my work was to examine whether the expression of HO-1 and 
S1P1  contribute  to  alternative  macrophage  activation.  In  this  regard,  the 
underlying molecular pathways of HO-1 and S1P1 induction and their relevance 
for  macrophage  polarization  should  be  identified.  The  following  main  points 
were experimentally addressed.   
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·  In the first part of my studies, I analyzed whether HO-1 was induced in 
primary human macrophages following treatment with supernatants from 
AC.  
 
·  Next, I investigated the signaling pathways, which are involved in the 
expression of HO-1 following incubation with supernatants from AC.  
 
·  Then, I identified the target genes of HO-1 being affected by treatment 
with supernatants from AC. 
 
·  As  unexpectedly  S1P1  expression  was  also  fostered  by  AC 
supernatants,  I  worked  out  whether  this  induction  was  specific  for 
alternative macrophage activating factors and whether the S1P receptor 
expression profile was altered in general. 
 
·  Finally, I analyzed the impact of S1P1 upregulation and trans-localization, 
which  was affected by AC supernatants, on the migratory potential of 
macrophages. 
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4  MATERIALS AND METHODS   
 
4.1  Materials 
 
4.1.1  Chemicals and reagents 
 
All chemicals were of the highest grade of purity commercial available. 
 
40% acrylamide/bis-acrylamide 
(29%:1.0% w/v) 
Carl Roth GmbH & Co. KG, Karlsruhe 
40% acrylamide/bis-acrylamide 
(37.5% : 1.0% w/v)  
Carl Roth GmbH & Co. KG, Karlsruhe 
4′,6-Diamidino-2-phenylindol 
(DAPI) 
Sigma-Aldrich
® Chemie GmbH, 
Deisenhofen 
ABsolute™ QPCR SYBR
® Green  ABgene
®, Hamburg 
Adenosine triphosphate (ATP)  Roche Diagnostics GmbH, Mannheim 
Agarose  PeqLab Biotechnologie GmbH, 
Erlangen 
Ammonium chloride (NH4Cl)  Merck KGaA, Darmstadt 
Ammonium persulfate (APS)  Sigma-Aldrich
® Chemie GmbH, 
Deisenhofen 
Ampicillin  Biomol
® GmbH, Hamburg 
BSA  Sigma-Aldrich
® Chemie GmbH, 
Deisenhofen 
Brome phenol blue  AppliChem GmbH, Darmstadt 
Calcium chloride (CaCl2)  Sigma-Aldrich
® Chemie GmbH, 
Deisenhofen 
Chloroform  Merck KGaA, Darmstadt 
Coelenterazine  BIOTREND
® Chemikalien GmbH, Köln 
Coenzyme A (lithium salt)  Sigma-Aldrich
® Chemie GmbH, 
Deisenhofen 
Diethyl pyrocarbonate (DEPC)  Carl Roth GmbH & Co. KG, Karlsruhe 
DMSO   Carl Roth GmbH & Co. KG, Karlsruhe 
Disodium hydrogen phosphate  
(Na2HPO4)  
Merck KGaA, Darmstadt 
Dithiothreitol (DTT)   Carl Roth GmbH & Co. KG, Karlsruhe 
D-luciferin  AppliChem GmbH, Darmstadt 
DNA loading dye (6x)  Fermentas GmbH, St. Leon-Rot 
Ethanol   Sigma-Aldrich
® Chemie GmbH, 
Deisenhofen 
Ethidium bromide  Sigma-Aldrich
® Chemie GmbH, 
Deisenhofen 
EDTA  Sigma-Aldrich
® Chemie GmbH, 
Deisenhofen 
Ficoll
TM PM 400  Amersham Biosciences Europe GmbH, 
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Forene
® (Isoflurane)  Abbot GmbH & Co. KG, Wiesbaden 
GeneRuler™ 100bp DNA Ladder  Fermentas GmbH, St. Leon-Rot 
Glucose  Carl Roth GmbH & Co. KG, Karlsruhe 
Glycerol  Carl Roth GmbH & Co. KG, Karlsruhe 
Glycine   Serva Electrophoresis GmbH, 
Heidelberg 
HEPES   Carl Roth GmbH & Co. KG, Karlsruhe 
Hydrochloric acid (HCl)  Merck KGaA, Darmstadt 
Isopropanol   Merck KGaA, Darmstadt 
JetPEI™  Polyplus-Transfection™, Illkirch 
(France) 
LB agar (Luria/Miller)   Carl Roth GmbH & Co. KG, Karlsruhe 
LB medium (Luria/Miller)   Carl Roth GmbH & Co. KG, Karlsruhe 
Magnesium carbonate hydroxide 
[(MgCO3)4 x Mg(OH)2] 
Sigma-Aldrich
® Chemie GmbH, 
Deisenhofen 
Magnesium chloride (MgCl2)  AppliChem GmbH, Darmstadt 
Magnesium sulfate (MgSO4)  Carl Roth GmbH & Co. KG, Karlsruhe 
Methanol (MeOH)   Carl Roth GmbH & Co. KG, Karlsruhe 
Nonidet P-40   ICN Biomedicals GmbH, Eschwege 
PageRuler™ Prestained Protein 
Ladder 
Fermentas GmbH, St. Leon-Rot 
Paraformaldehyde (PFA)  Merck KGaA, Darmstadt 
peqGOLD RNAPure™   Peqlab Biotechnologie GmbH, Erlangen 
PMSF  Sigma-Aldrich
® Chemie GmbH, 
Deisenhofen 
Phosphatase inhibitor mix 
PhosSTOP 
Roche Diagnostics GmbH, Mannheim 
Phosphoric acid (H3PO4)  Sigma-Aldrich
® Chemie GmbH, 
Deisenhofen 
Poly(dI-dC)  Pharmacia, Uppsala (Sweden)  
Potassium chloride (KCl)   Merck KGaA, Darmstadt 
Potassium hydrogen carbonate 
(KHCO3)  
Merck KGaA, Darmstadt 
Potassium hydrogen phosphate 
(KH2PO4)  
Merck KGaA, Darmstadt 
Potassium hydroxide (KOH)  Carl Roth GmbH & Co. KG, Karlsruhe 
Protease inhibitor mix complete  Roche Diagnostics GmbH, Mannheim 
Proteinase K  Sigma-Aldrich
® Chemie GmbH, 
Deisenhofen 
Sodium borate (Na2B4O7)   Merck KGaA, Darmstadt 
Sodium chloride (NaCl)   Merck KGaA, Darmstadt 
Sodium dodecyl sulfate (SDS)  Carl Roth GmbH & Co. KG, Karlsruhe 
Sodium fluoride (NaF)  Sigma-Aldrich
® Chemie GmbH, 
Deisenhofen 
Sodium hydroxide (NaOH)  Merck KGaA, Darmstadt 
Sucrose  Carl Roth GmbH & Co. KG, Karlsruhe 
Tetraethylendiamine (TEMED)   Carl Roth GmbH & Co. KG, Karlsruhe 
Tricine  Carl Roth GmbH & Co. KG, Karlsruhe 
Tris  Carl Roth GmbH & Co. KG, Karlsruhe 
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Trypan blue  Biochrom AG, Berlin 
Tryptone  Sigma-Aldrich
® Chemie GmbH, 
Deisenhofen 
Tween
® 20   Carl Roth GmbH & Co. KG, Karlsruhe 
Urea  Sigma-Aldrich
® Chemie GmbH, 
Deisenhofen 
VECTASHIELD
® Hard Set™ 
Mounting Medium 
Vector Laboratories, Inc., Burlingam 
(USA) 
Yeast extract   Life Technologies, Paisley (Scotland) 
 
 
4.1.2  Buffers and solutions  
 
Unless indicated otherwise, all buffers and solutions were manufactured and 
diluted  in  bidestilled  H2O  and  adjustment  of  pH  was  performed  with  HCl  or 
NaOH. 
 
Antibody solution: 
TTBS            50 % (v/v) 
Blocking buffer        50 % (v/v) 
 
Blocking buffer        Rockland Immunochemicals Inc.,  
            Gilbertsville (USA) 
 
Blotting buffer (10 x): 
Tris             250 mM 
Glycine           1.9 M 
Methanol          20% (v/v) 
pH             8.3    
 
Buffer D: 
HEPES          20 mM 
Glycerol          20 % (v/v) 
KCl            100 mM 
EDTA           0.5 mM 
Nonidet P-40          0.25 % (v/v) 
DTT            2 mM 
PMSF           0.5 mM 
NaF            10 mM 
Protease inhibitor mix      1 x 
Phosphatase inhibitor mix     1 x 
pH (adjusted with KOH)      7.9 
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Buffer F: 
Ficoll
TM PM 400        20 % (w/v) 
HEPES          100 mM 
KCl            300 mM 
DTT            10 mM 
PMSF           0.5 mM 
NaF            10 mM 
Protease inhibitor mix      1 x 
Phosphatase inhibitor mix     1 x 
pH (adjusted with KOH)      7.9 
 
DEPC-treated H2O 
DEPC           1 ml 
H2O            999 ml 
 
Firefly assay reagent:  
ATP            530 µM 
Coenzyme A         213 mg/l 
D-luciferin          470 mM 
DTT            33.3 µM 
EDTA-K
+           100 µM 
(MgCO3)4 x Mg(OH)2      1.07 mM 
MgSO4          2.67 mM 
Tricine          20 mM 
pH            7.8 
 
Firefly lysis buffer (5 x): 
DTT            10 mM 
Glycerol          50% (v/v) 
Tris            125 mM 
Triton X-100         5% (v/v) 
pH (adjusted with H3PO4)      7.8 
 
Genotyping lysis buffer 
NaOH           25 mM 
EDTA           0.2 mM 
pH            12.0 
 
Genotyping neutralization buffer 
Tris            40 mM 
pH            5.0 
 
Hypotonic cell lysis buffer: 
HEPES           10 mM 
MgCl2             2 mM 
EDTA           100  M 
KCl             10 mM 
DTT             1 mM 
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Protease inhibitor mix      1 x 
Phosphatase inhibitor mix     1 x 
pH (adjusted with KOH)      7.9 
 
Leukocyte washing buffer: 
EDTA           2 mM 
in PBS 
 
Lower Tris buffer:  
Tris            1.5 M  
pH             8.8 
 
Nuclear lysis buffer: 
HEPES          50 mM 
KCl             50 mM 
NaCl            300 mM 
EDTA           100  M 
Glycerol           10% (v/v) 
DTT             1 mM 
PMSF           0.5 mM 
NaF            10 mM 
Protease inhibitor mix      1 x 
Phosphatase inhibitor mix     1 x 
pH             7.9 
 
Passive lysis buffer      Promega GmbH, Mannheim 
 
PBS:  
NaCl            137 mM 
KCl             2.7 mM 
Na2HPO4           8.1 mM 
KH2PO4           1.5 mM 
pH             7.4 
 
PFA (4%): 
PFA            4% (v/v) 
Sucrose          10% (v/v) 
in PBS 
pH            7.4 
 
Protein lysis buffer: 
Tris             50 mM 
EDTA           5 mM 
NaCl            150 mM 
Nonidet P-40         150 mM 
PMSF           0.5 mM 
DTT             1 mM 
Protease inhibitor mix       1 x 
pH            8.0 
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Renilla assay reagent:  
Tris            25 mM 
NaCl            100 mM 
CaCl2           1 mM 
Coelenterazine        90 µM 
pH            7.5 
 
Running buffer (glycerol tolerant)  Amersham Biosciences Europe GmbH, 
Freiburg 
 
SDS-PAGE sample buffer (4 x): 
Tris             125 mM 
10% SDS           2% (v/v) 
Glycerol           20% (v/v) 
Brome phenol blue       0.002% (w/v) 
DTT             5 mM 
pH             6.9 
 
SDS-PAGE running buffer (10 x): 
Tris            250 mM 
Glycine           1.9 M 
SDS             7 mM 
pH             8.3 
 
STE (2 x): 
Tris (pH 8.0)         10 mM 
NaCl            50 mM 
EDTA           1 mM 
 
TBS (10 x): 
Tris            500 mM 
NaCl            1.5 M 
pH             7.4 
 
TBE (5 x):   
Tris             445 mM 
Na2B4O7           445 mM 
EDTA           10 mM 
 
TE:  
Trypsin           0.5 g/l 
EDTA           0.2 g/l 
in PBS 
 
TTBS: 
TBS             1 x 
Tween 20           0.06% (v/v) 
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Upper Tris buffer:  
Tris             0.5 M  
pH             6.8  
 
Whole cell protein lysis buffer:  
Urea            6.65 M 
Glycerol          10% (v/v) 
SDS            1% (v/v) 
Tris (pH 6.8)         10 mM 
pH            7.4 
 
 
4.1.3  Stimulants and inhibitors 
 
Bilirubin  Sigma-Aldrich
® Chemie GmbH, 
Deisenhofen 
Tricarbonyldichlororuthenium(II) 
dimer (CORM-2) 
Sigma-Aldrich
® Chemie GmbH, 
Deisenhofen 
Diethylenetriamine-NO (Deta-NO)  Sigma-Aldrich
® Chemie GmbH, 
Deisenhofen 
Dimethylsphingosine (DMS)  Biomol
® GmbH, Hamburg 
Fludarabine  Sigma-Aldrich
® Chemie GmbH, 
Deisenhofen 
IFN-g (human)  Roche Diagnostics GmbH, Mannheim 
IL-4 (human)  PeproTech GmbH, Hamburg 
IL-10 (human)  PeproTech GmbH, Hamburg 
JAK Inhibitor I (InSolution™)  Merck KGaA, Darmstadt 
LPS (Escherichia coli, serotype 
0127:B8) 
Sigma-Aldrich
® Chemie GmbH, 
Deisenhofen 
SB203580  Alexis
® Biochemicals, Grünberg 
Sphingosine-1-phosphate (S1P)  Avanti
® Polar Lipids, Inc., Alabaster 
(USA) 
Staurosporine  Sigma-Aldrich
® Chemie GmbH, 
Deisenhofen 
STA-21  Biomol
® GmbH, Hamburg 
VPC 23019   Avanti
® Polar Lipids, Inc., Alabaster 
(USA) 
 
CORM-2 was freshly dissolved in DMSO for each experiment. As a negative 
control, CORM-2 was inactivated (iCORM) according to a previously described 
method (197).  
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4.1.4  Cell lines and primary cells  
 
Primary human monocytes: 
Primary human monocytes were isolated from buffy coats, which were obtained 
from  DRK-Blutspendedienst  Baden  Württemberg-Hessen,  Institut  für 
Transfusionsmedizin und Immunhämatologie, Frankfurt am Main. 
 
Primary murine peritoneal macrophages: 
Murine  peritoneal  macrophages  were  isolated  from  6-10  week-old  C57Bl/6 
EDG-1
fl/fl x F4/80
Cre/+ or C57Bl/6 EDG-1
fl/fl x F4/80
+/+ mice. 
 
Jurkat T cells (DSMZ GmbH, Braunschweig):
 
Jurkat T cells are derived from a 14 year-old boy with acute lymphatic leukemia. 
This T cell line was established in 1977 (198). 
 
 
4.1.5  Mice 
 
Mice  with  a  S1P1  knockout  in  F4/80  positive  cells  (C57Bl/6  EDG-1
fl/fl  x 
F4/80
Cre/+)  and  control  littermates  (C57Bl/6  EDG-1
fl/fl  x  F4/80
+/+)  were  kindly 
provided by Dr. Bodo Levkau (Institute of Pathophysiology, University of Essen 
Medical  School).  These  mice  were  generated  by  breeding  F4/80  cyclization 
recombinase (Cre) knockin mice (199) with S1P1
loxP mice, in which exon 2 of 
the S1P1 gene was flanked by locus of X-over of P1 (loxP) sites (200). Mice 
were  kept  in  the  Zentrale  Forschungseinrichtung  of  the  Johann  Wolfgang 
Goethe-University Frankfurt, Frankfurt am Main in polysulphon cages with filter 
cover containing 5-10 mice in each cage. Cages were equipped with litter and 
pellet food as well as water ad libitum. Experiments followed the guidelines of 
the Hessian animal care and use committee. 
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4.1.6  Bacteria  
 
XL1-Blue  supercompetent  bacteria  [Stratagene  GmbH,  Amsterdam 
(Niederlande)]. Genotype: recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac 
[F´ proAB lacI
qZDM15 Tn10(Tet
R)]. 
 
XL-10-Gold
Ò Ò Ò Ò  ultracompetent  bacteria  [Stratagene  GmbH,  Amsterdam 
(Niederlande)]. Genotype: Tet
R D(mcrA)183 D(mcrCB-hsdSMR-mrr)173 endA1 
supE44 thi-1 recA1 gyrA96 relA1 lac Hte [F´ proAB lacI
qZDM15 Tn10 (Tet
R) 
Amy Cam
R]. 
 
 
4.1.7  Reagents for cell culture 
 
FCS Gold  PAA Laboratories GmbH, Cölbe 
Human plasma (AB positive 
donor) 
DRK-Blutspendedienst Baden 
Württemberg-Hessen, Institut für 
Transfusionsmedizin und 
Immunhämatologie, Frankfurt am Main 
L-glutamine  PAA Laboratories GmbH, Cölbe 
Lymphocyte separation medium 
LSM 1077  
PAA Laboratories GmbH, Cölbe 
PBS (Instamed 9.55 g/ml)   Biochrom AG, Berlin 
Penicillin/streptomycin   PAA Laboratories GmbH, Cölbe 
Trypsin/EDTA (3.5 U/mg, porcine)  PAA Laboratories GmbH, Cölbe 
 
 
4.1.8  Media for cell culture 
 
Different  culture  media  were  used  on  the  basis  of  Roswell  Park  Memorial 
Institute  (RPMI)  1640,  which  was  obtained  from  PAA  Laboratories  GmbH 
(Cölbe). FCS and human plasma were heat-inactivated by incubation at 56° C 
for 30 min.  
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RPMI with FCS   
RPMI 1640   
FCS  10% 
L-Glutamin  2 mM 
Penicillin  100 U/ml 
Streptomycin  0,1 mg/ml 
   
RPMI with human plasma   
RPMI 1640   
Human plasma  10% 
L-Glutamin  2 mM 
Penicillin  100 U/ml 
Streptomycin  0,1 mg/ml 
   
RPMI without plasma   
RPMI 1640   
L-Glutamin  2 mM 
Penicillin  100 U/ml 
Streptomycin  0,1 mg/ml 
 
 
4.1.9  Media for bacteria culture  
 
SOC medium   
Tryptone  20 g/l 
Yeast extract  5 g/l 
NaCl  0.5 g/l 
MgCl2   10 mM 
KCl  2.5 mM 
Glucose  2 mM 
 
 
4.1.10   Antibodies  
 
Primary antibodies:  
Anti-actin (rabbit, polyclonal)  Sigma-Aldrich
® Chemie GmbH, 
Deisenhofen 
Anti-Adora A2A (rabbit, polyclonal)  Merck KGaA, Darmstadt 
Anti-Bcl-XL (mouse, monoclonal)  BD Transduction Laboratories™, 
Heidelberg 
Anti-HO-1 (rabbit, polyclonal)  Biomol
® GmbH, Hamburg 
Anti-S1P1 (rabbit, polyclonal)  Orbigen Inc., San Diego (USA)  
Anti-S1P1 (rabbit, polyclonal)  ProSci Inc., Poway (USA) 
Anti-S1P1 (mouse, monoclonal)  Abcam
® plc, Cambridge (UK) 
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Secondary antibodies: 
IRDye
® 800-labeled donkey anti-
rabbit  
LI-COR
® Biosciences GmbH, Bad 
Homburg 
IRDye
® 800-labeled donkey anti-
mouse  
LI-COR
® Biosciences GmbH, Bad 
Homburg 
Alexa Fluor
® 546-labeled goat 
anti-mouse 
Invitrogen™ GmbH, Karlsruhe 
 
 
 
4.1.11   Oligonucleotides 
 
Labeled  oligonucleotides  were  obtained  from  metabion  GmbH  (Martinsried), 
whereas unlabeled oligonucleotides were purchased from biomers.net GmbH 
(Ulm). 
 
IRDye
®700-labeled oligonucleotides for EMSA analysis: 
The  sequence  of  the  human  HO-1  promoter  was  obtained  using  the  online 
transcriptional  regulatory  element  database  CSH.  The  online  tool  TFSearch 
provided  the  putative  STAT  binding  sites  located  within  this  sequence. 
According to this sequence the following oligonucleotides for the STAT binding 
site at -2361 bp to -2369 bp of the human HO-1 promoter were purchased. 
5’- IRDye
®700-AGG CAC TAT TCC AGG AAC TGG GAA T-3’ 
5’- IRDye
®700-ATT CCC AGT TCC TGG AAT AGT GCC T-3’ 
 
Unlabeled oligonucleotides for competitive EMSA analysis: 
STAT1  oligonucleotides  were  designed  according  to  the  sequence  sc-2573 
provided  by  Santa  Cruz  Biotechnology
®,  Inc.,  Heidelberg  (consensus  site  in 
boldface letters): 
5’-CAT GTT ATG CAT ATT CCT GTA AGT-3’ 
5’-ACT TAC AGG AAT ATG CAT AAC ATG-3’ 
STAT3  oligonucleotides  were  designed  according  to  the  sequence  sc-2571 
provided  by  Santa  Cruz  Biotechnology
®,  Inc.,  Heidelberg  (consensus  site  in 
boldface letters): 
5’-GAT CCT TCT GGG AAT TCC TAG ATC-3’ 
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Oligonucleotides  for  the  STAT  binding  site  at  -2361  bp  to  -2369  bp  of  the 
human  HO-1  promoter  with  a  point  mutation  to  impair  STAT3  binding  (point 
mutation in boldface letters):  
5’-AGG CAC TAT TCC AGG CCC TGG GAA T-3’ 
5’-ATT CCC AGG GCC TGG AAT AGT GCC T-3’ 
 
Primers for quantitative PCR:  
For  human  ribosomal  18S  RNA,  actin,  HO-1,  S1P2,  S1P3  and  VEGF  the 
following primers were obtained from biomers.net GmbH (Ulm). 
Human ribosomal 18S RNA: 
5’-GTA ACC CGT TGA ACC CCA TT-3’ 
5’-CCA TCC AAT CGG TAG TAG CG-3’ 
Human actin: 
5’-TGA CGG GGT CAC CCA CAC TGT GCC CAT CTA-3’ 
5’-CTA GAA GCA TTT GCG GTG GAC GAT GGA GGG-3’ 
Human HO-1: 
5’-GCC ACC AAG TTC AAG CAG CT-3’ 
5’-CAG TGC CCA CGG TAA GGA AG-3’ 
Human S1P2: 
5’-AGT TGC ACT ATT TGG GGC AC-3’ 
5’-GGT GGC TGT TTT TGA AAG GA-3’ 
Human S1P3: 
5’-GCT TCA GGA AAT GGA AGC TG-3’ 
5’-TCA GGA TGC TGT GAA ACT GC-3’ 
Human VEGF:  
5’-TAC CTC CAC CAT GCC AAG TG-3’ 
5’-AAG ATG TCC ACC AGG GTC TC-3’ 
For  human  adenosine  receptor  A2A  (Adora  A2A),  Bcl-2,  Bcl-XL,  HLA-DMB, 
indoleamine-2,3-dioxygenase  (IDO)  and  S1P1,  validated  QuantiTect  Primer 
Assays were purchased from QIAGEN GmbH (Hilden). Sequence information is 
restricted to the manufacturer. 
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Primers for the detection of the Cre allele (199): 
5’-CTG ATG GTG GCA ACT CAG C-3’  (F4/80 3.4) 
5’-GCA TGC ACC GGT AAT GCA GGC-3’  (Cre rev 1)   
 
Primers for the detection of the F4/80 wild-type allele (199): 
5’-CTG ATG GTG GCA ACT CAG C-3’  (F4/80 3.4) 
5’-AGA GGA GCA GCC AAA AGC CCC-3’  (F4/80 exon 1) 
 
Primers for the detection of the loxP site flanked exon 2 of the S1P1 allele: 
5’-GAG CGG AGG AAG TTA AAA GTG-3’  (P1) 
5’-CCT CCT AAG AGA TTG CAG CAA-3’  (P2) 
 
Primers for site-directed mutagenesis:  
5’-CCA GGC ACT ATT CCA GGC CCT GGG AAT TTA CAA AGC-3’ 
5’-GCT TTG TAA ATT CCC AGG GCC TGG AAT AGT GCC TGG-3’  
Using these primers, a point mutation was introduced into the putative STAT 
binding site at position -2361 bp to -2369 bp within the human HO-1 promoter, 
to  impair  STAT3  binding.  Thus,  sequence  was  mutated  from  5’-TTC 
CAG GAA-3’ to 5’-TTC CAG GCC-3’. 
 
Specific small interferring (si)RNA: 
Commercially  available  validated  siRNA  against  HO-1  (QIAGEN  GmbH, 
Hilden),  VEGFA  (QIAGEN  GmbH,  Hilden)  or  S1P1  (Ambion
®/Applied 
Biosystems,  Darmstadt)  was  used.  Sequence  information  is  restricted  to  the 
manufacturer. Specificity was assured using siCONTROL non-targeting Duplex 
#1 [Dharmacon Inc., Lafayette (USA)]. 
 
 
4.1.12   Reporter plasmids    
 
The plasmids p1.0-Luc and p1.3-Luc were a gift from Dr. Jianzhu Chen (123). 
The  plasmids  phHOLUC40,  phHOLUC(-2782)  and  phHOLUC(-1976)  were 
kindly provided by Dr. Shigeru Takahashi (201). 
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p1.0-Luc: 
The plasmid is based on the vector pGL3-basic and carries a 1 kb fragment of 
the 5’-flanking region of the murine S1P1 gene.  
 
p1.3-Luc: 
The vector contains a 1.3 kb fragment of the 5’-flanking region of the murine 
S1P1 gene and is based on the vector pGL3-basic.   
 
phHOLUC40: 
The plasmid carries a 4 kb fragment of the 5’-flanking region of the human HO-1 
gene and is based on the vector pGL3-basic.  
 
phHOLUC(-2782): 
On  the basis of  the  vector  pGL3-basic  the plasmid  contains  2782  bp  of  the 
5’-flanking region of the human HO-1 gene. 
 
phHOLUC(-1976): 
The plasmid carries 1976 bp of the 5’-flanking region of the human HO-1 gene 
and is based on the vector pGL3-basic.  
 
phHOLUC(-2782ptm): 
This  plasmid  was  created  based  on  the  vector  phHOLUC(-2782)  by  site-
directed mutagenesis (4.2.9). A point mutation of the putative STAT binding site 
at  position  -2361  bp  to  -2369  bp  within  the  human  HO-1  promoter  was 
introduced to impair STAT3 binding.  
 
pRL-CMV (Promega GmbH, Mannheim): 
The vector was used in combination with the HO-1 or S1P1 reporter vector to 
co-transfect mammalian cells. It contains a cDNA encoding Renilla luciferase, 
whose expression is very high due to a CMV enhancer. 
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4.1.13   Kits 
 
BD™ Cytometric Bead Array, 
Human VEGF Flex Set 
BD Biosciences, Heidelberg 
Human Macrophage 
Nucleofector
® Kit 
Lonza AG, Köln 
HiSpeed
® Plasmid Maxi Kit  QIAGEN GmbH, Hilden 
iScript™ cDNA Synthesis Kit  Bio-Rad Laboratories GmbH, München 
Taq DNA Polymerase Kit  Invitrogen™ GmbH, Karlsruhe 
QuikChange
® II XL Site-Directed 
Mutagenesis Kit  
Stratagene GmbH, Amsterdam 
(Netherlands) 
Standard DC Protein Assay Kit  Bio-Rad Laboratories GmbH, München 
 
 
4.1.14   Instruments  
 
ApoTome system  Carl Zeiss Microimaging GmbH, 
Offenbach/Main 
Analysis scale AE 163  Mettler-Toledo GmbH, Giessen 
Autoclave ELC 5075   Tuttnauer Co. Ltd., New York (USA) 
Bacteria clean bench HERA 
guard 
Heraeus Holding GmbH, Hanau 
Bacteria incubator innova
® 44  New Brunswick Scientific GmbH, 
Nürtingen 
Cell counter CASY
®, model TT  Innovartis AG, Reutlingen 
Cell culture clean bench HERA 
safe 
Heraeus Holding GmbH, Hanau 
Cell culture incubator HERA cell 
240 
Heraeus Holding GmbH, Hanau 
Cell homogenizer Sonifier
® 250   Branson Ultraschall, Dietzenbach 
Centrifuge 5415 R   Eppendorf AG, Hamburg 
Centrifuge 5810 R   Eppendorf AG, Hamburg 
Elektroblotter Trans-Blot
® SD 
Semi-Dry Transfer Cell 
Bio-Rad Laboratories GmbH, München 
Falcon shaker RM5  Karl Hecht KG, Sondheim/Röhn 
Flow cytometer FACSCanto™   BD Biosciences GmbH, Heidelberg 
Fluorescence microscope 
Axiovert 200M 
Carl Zeiss Microimaging GmbH, 
Offenbach/Main 
Fluorescence microscope 
camera AxioCam MRm 
Carl Zeiss Microimaging GmbH, 
Offenbach/Main 
Freezer Premium (-20° C)  Liebherr Hausgeräte GmbH, 
Ochsenhausen 
Freezer VIP™ Series (-80° C)  Sanyo Fisher Sales GmbH , München 
Gel documentation system 
Image Documentation & 
Analysis 
Raytest GmbH, Straubenhardt 
Ice machine MF 30  Scotsman
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Infrared imaging system 
Odyssey 
LI-COR
® Biosciences GmbH, Bad 
Homburg 
Magnetic stirrer MR 3000  Heidolph Instruments GmbH & Co. KG, 
Schwabach 
Microscope CKX31  Olympus Deutschland GmbH, Hamburg 
Multilabel reader Mithras LB 940   Berthold Technologies GmbH, Bad 
Wildbad 
Nucleofector
® II  Lonza Cologne AG, Köln 
Orbit Shaker Titramax 100  Heidolph Instruments GmbH & Co. KG, 
Schwabach 
PCR machine Mastercycler  Eppendorf AG, Hamburg 
pH meter CG 842  Schott AG, Mainz 
Pipettes (10  l, 100  l, 1000  l)   Eppendorf AG, Hamburg 
Pipetus
®-akku  Hirschmann Laborgeräte GmbH & Co. 
KG, Eberstadt 
Power Supply PowerPac™ HC  Bio-Rad Laboratories GmbH, München 
Real-Time PCR Detection 
System MyiQ™ Single Color 
Bio-Rad Laboratories GmbH, München 
Refrigerator Profi Line  Liebherr Hausgeräte GmbH, 
Ochsenhausen 
Rocker platform Titramax 100  Heidolph Instruments GmbH & Co. KG, 
Schwabach 
SDS gelelectrophoresis system 
Mini-PROTEAN 3 
Bio-Rad Laboratories GmbH, München 
Spectrophotometer NanoDrop
® 
ND-1000 
NanoDrop Technologies, Inc., Wilmington 
Sub-Cell
® GT Agarose Gel 
Electrophoresis System  
Bio-Rad Laboratories GmbH, München 
Table centrifuge Micromax  IEC, Needham Heights (USA) 
Thermomixer compact   Eppendorf AG, Hamburg 
Trans-Blot
® SD Semi-Dry 
Electrophoretic Transfer Cell  
Bio-Rad Laboratories GmbH, München 
Water system PURELAB 
Classic UVF 
Elga Labwater, Celle 
Vortexer REAX top  Heidolph Instruments GmbH & Co. KG, 
Schwabach 
Water bath SW-20C  Julabo Labortechnik GmbH, Seelbach 
 
 
4.1.15   Software 
 
AxioVision Rel. 4.4  Carl Zeiss Microimaging GmbH, 
Offenbach/Main 
BD FACSDivaTM Software   BD Biosciences GmbH, Heidelberg 
FCAP Array 1.0.1  Soft Flow, Burnsville (USA) 
Gene Expression Macro 1.1  Bio-Rad Laboratories GmbH, München 
ND-1000 3.2.1  NanoDrop Technologies, Inc., Wilmington 
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Odyssey 2.1  LI-COR
® Biosciences GmbH, Bad 
Homburg 
MyiQ™ 1.0  Bio-Rad Laboratories GmbH, München 
TESS  http://www.cbil.upenn.edu/cgi-
bin/tess/tess) 
TFSearch  http://www.cbrc.jp/research/db/ 
TFSEARCH.html 
Transcriptional regulatory 
element database CSH 
http://rulai.cshl.edu/cgi-
bin/TRED/tred.cgi?process=home 
MikroWin 2000   Mikrotek Laborsysteme GmbH, Overath 
AxioVision Rel. 4.4  Carl Zeiss Microimaging GmbH, 
Offenbach/Main 
BD FACSDivaTM Software   BD Biosciences GmbH, Heidelberg 
FCAP Array 1.0.1  Soft Flow, Burnsville (USA) 
 
 
4.1.16   Other material 
 
ABgene
® PCR Plates (96-well)  ABgene
®, Hamburg 
ABsolute™ QPCR Seal  ABgene
®, Hamburg 
Cover slips  Menzel-Gläser GmbH & Co. KG, 
Braunschweig 
MILLEX
®-HV PVDF Filters 
(0.22 µm pore) 
Millipore GmbH, Schwalbach 
Glassware  Schott AG, Mainz 
Membrane PROTRAN
®  Whatman
® Schleicher & Schuell, Dassel 
Needles (20-gauge)  Becton Dickinson GmbH, Heidelberg 
Object slides  Süsse GmbH, Gudensberg 
Pellet food (10 mm pellets, 
rat/mouse) 
Ssniff Spezialdiäten GmbH, Soest 
Plastic material   Becton Dickinson GmbH, Heidelberg 
Eppendorf AG, Hamburg 
Greiner bio-one GmbH, Frickenhausen 
Sarstedt AG & Co., Nümbrecht 
Polysulphon cage with filter 
cover 
Tecniplast GmbH, Hohenpreißenberg 
Ring-shaped stickers  Avery
® Dennison Zweckform, Holzkirchen 
Syringes (10 ml)  B.Braun Melsungen AG, Melsungen 
Whatman
® paper GB 003  Whatman
® Schleicher & Schuell, Dassel 
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4.2  Methods    
 
4.2.1  Cell culture 
 
4.2.1.1   Culture of Jurkat T cells 
Jurkat T cells were cultured in RPMI with FCS. Cells were kept in a humidified 
atmosphere of 5% CO2 in air at 37° C and were transferred twice a week.  Cell 
numbers were determined using the CASY
® cell counter system. 
 
 
4.2.1.2   Human monocyte isolation and culture 
Human monocytes were isolated as described previously (202). In brief, using 
Ficoll-Hypaque  gradients,  monocytes  were  isolated  from  buffy  coats.  50  ml-
Leukosep
® tubes were layered with 15 ml lymphocyte separation medium and 
blood cells were added, followed by density gradient centrifugation (440 x g, 
35 min, RT, without brake). Peripheral blood mononuclear cells were collected, 
washed twice with leukocyte washing buffer, seeded in 10-cm dishes in RPMI 
without  plasma  and  subsequently  incubated  for  1  h  at  37° C  to  allow  their 
adherence  to  culture  dishes.  After  removing  non-adherent  cells,  monocytes 
were differentiated into macrophages with RPMI with human plasma for 7 days.  
 
 
4.2.1.3   Murine peritoneal macrophage isolation and culture 
Following anesthetization of mice with Forene
®, the spinal cord was severed by 
cervical dislocation. Mice were injected with 10 ml ice cold PBS intraperitoneal. 
Then, PBS was spaced in the peritoneum and removed with a syringe. After 
centrifugation (500 x g, 5 min), cells of one mouse were seeded in two wells of 
a 12-well plate in RPMI with FCS. After 4 h of incubation, cells were washed 
twice  with  PBS  to  remove  non-adherent  cells.  Cells  were  incubated  for 
3-5 days,  washing  them  each  two  days  with  PBS  before  starting  the 
experiments.    
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4.2.1.4   Generation of conditioned media 
Apoptotic Jurkat cells were generated by incubating cells for 3 h with 0.5 µg/ml 
staurosporine in RPMI without serum (35). Necrosis in Jurkat cells, cultured in 
RPMI with FCS, was induced by incubating cells for 30 min at 56° C (35). AC or 
NC were washed twice with PBS and incubated for another 3-h period in RPMI 
with human plasma (for further treatment of primary human macrophages) or 
RPMI  with  FCS  (for  further  treatment  of  primary  murine  peritoneal 
macrophages).  Conditioned  medium  (CM)  was  harvested  by  centrifugation 
(1000 x g, 10 min) and filtration through 0.22 µm pore filters to remove apoptotic 
bodies. The procedure to generate CM from VC was equivalent. Jurkat cells 
were incubated in RPMI with FCS, omitting a death stimulus. DMS, an inhibitor 
of sphingosine kinases, was used to generate AC-CM without S1P. 20 µM DMS 
was added simultaneously with staurosporine to Jurkat cells during the initiation 
of  apoptosis  (35).  To  obtain  macrophage  CM  (MF-CM),  macrophages  were 
incubated  with  AC-CM  for  2  h,  washed  twice  with  PBS  and  incubated  for 
another  4-h  period  in  RPMI  with  human  plasma.  MF-CM  was  harvested  by 
centrifugation  (1000  x  g,  10  min).  For  protein  degradation,  MF-CM  was 
incubated with 50 µg/ml proteinase K at 37° C for 1  h, followed by inactivation of 
proteinase  K  at  100° C  for  1  h.  Cells  were  exposed  to  CM  for  the  times 
indicated.  Unless  indicated  otherwise,  inhibitors  were  pre-incubated  for  1  h 
each. CM was generated using 1 x 10
7 Jurkat cells and later on added to 2 x 
10
6 macrophages (ratio 5:1). MF-CM was directly transferred from generator to 
recipient cells.  
 
 
4.2.2  Transient transfection of eukaryotic cells 
 
4.2.2.1   Transfection of plasmid DNA     
For reporter assay 10% of one buffy coat monocyte preparation were seeded in 
one 12-well plate. After 7 days, macrophages were co-transfected with 900 µg 
of HO-1 or S1P1 promoter constructs and 100 µg of Renilla luciferase control 
vector pRL-CMV using the jetPEI™ transfection reagent. Briefly, for each well, 
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150 nM NaCl. Mixtures were vortexed and spinned-down briefly. Then, jetPEI™ 
solution  was  added  to  DNA  mixture,  vortexed  and  spinned  down.  After 
incubation  for  30  min  at  RT  100  µl/well  of  the  solution  were  added  to 
macrophages. Macrophages were incubated for 24 h, medium was changed 
and  macrophages  were  incubated  for  another  24  h  followed  by  individual 
stimulation. Following individual incubations firefly luciferase as well as Renilla 
luciferase activity were determined. 
 
 
4.2.2.2   Transfection of siRNA 
For Western blot analysis (4.2.3) and quantitative PCR (4.2.5), primary human 
macrophages  were  transfected  with  the  respective  siRNA  using  Human 
Macrophage  Nucleofector
Ò  Kits  and  the  Nucleofector
®  II.  Primary  human 
macrophages were removed from dishes by washing them with PBS prior to 
their incubation with TE for 15 min at 4° C. Then, m acrophages were incubated 
for 1 h at 37° C. Thereafter, macrophages were rinse d-off and 1.5 x 10
6 cells 
were harvested by centrifugation (200 x g, 10 min). Pellet was resuspended 
Human Macrophage Nucleofector
® Solution and mixed with 3 µg siRNA. After 
transfer  of  the  mixture  into  an  appropriate  cuvette,  nucleofection  was 
performed. Cells were seeded in 10-cm dishes in 5 ml pre-warmed RPMI with 
human  plasma  and  incubated  for  48  h  prior  to  the  use  in  the  individual 
experiments. 
 
 
4.2.3  Western immunoblotting 
 
To investigate changes in protein expression, proteins were isolated, separated 
by SDS-PAGE and detected by Western blotting.  
 
4.2.3.1   Isolation of proteins 
For Western immunoblotting, cells were incubated as indicated in the individual 
experiments, scraped-off, lysed in various volumes (75-200 µl, depending on 
the  mass  of  the  cell  pellet)  ice  cold  protein  lysis  buffer  (or  in  the  case  of 
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Lysates were incubated on ice for 30 min and vortexed each 10 min for 10 sec. 
After centrifugation (16000 x g, 30 min, 4° C) supernatants were collected and 
protein content was determined according to the Lowry method. 
 
 
4.2.3.2   Protein determination (Lowry method) 
The  protein  content  of  cell  lysates  was  determined  using  the  Standard  DC 
Protein  Assay  Kit,  which  is  based  on  the  Lowry  method  (203).  Briefly,  a 
standard dilution series of BSA in H2O was prepared (0.625-10 mg/ml). 2 µl of 
samples as well as standards were pipetted in duplicates into a 96-well plate 
and 20 µl solution A were added. The colorimetric reaction was started by the 
addition  of  160  µl  solution  B.  After  incubation  for  15  min  (RT,  shaking), 
extinction was measured at 750 nm using the Mithras LB 940 multilabel reader.  
 
 
4.2.3.3   SDS-PAGE  
40-80 µg  protein  was  filled-up  to 30  µl  with  H2O  and 10  µl 4  x  SDS-PAGE 
sample buffer was added. Samples were denatured at 100° C for 10 min and 
immediately  put  on  ice  for  2  min.  Proteins  were  resolved  on  SDS 
polyacrylamide gels consisting of an upper stacking gel and a lower separating 
gel with 1 x SDS-PAGE running buffer using the Mini-PROTEAN 3 system. The 
gel composition is listed in table 1. 
 
       Table 1. Composition of SDS polyacrylamide gels. 
Separating gel  Stacking gel 
 
12%  4% 
40% acrylamide/bis-acrylamide 
(37.5%:1.0% w/v) 
3 ml  300 µl 
Lower Tris buffer  2.5 ml  - 
Upper Tris buffer  -  750 µl 
10% (w/v) SDS  100 µl  30 µl 
H2O  4.4 ml  1.95 ml 
10% (w/v) APS  50 µl  50 µl 
TEMED  5 µl  5 µl 4 Materials and methods                                                                                    56                                                                                   
4.2.3.4   Western blotting 
Following SDS-PAGE, proteins were transferred onto nitrocellulose membranes 
by semi-dry blotting. Unspecific binding was blocked with blocking buffer for 2 h. 
Primary  antibody  was  added  in  antibody  solution  according  to  the 
manufacturer’s instructions and incubated either for 2 h at RT or overnight at 
4° C.  Membranes  were  washed  three  times  for  5  min  ea ch  with  TTBS. 
Thereafter,  membranes  were  incubated  with  a  secondary  near  infrared  dye 
(IRDye
®) conjugated antibody in antibody solution for 1 h and again washed 
three times for 5 min each with TTBS. Specific proteins were detected and their 
expression  was  quantified  compared  to  actin  expression  using  the  Odyssey 
infrared imaging system.  
 
 
4.2.4  Electrophoretic mobility shift assay (EMSA)   
 
4.2.4.1   Oligonucleotide annealing 
For oligonucleotide annealing 50 µl of both oligonucleotides of the respective 
pair (100 pmol/µl) were mixed with 100 µl 2 x STE and incubated at 90° C for 
10 min. Afterwards, oligonucleotides were cooled-down to 15° C with 1° C/min. 
 
 
4.2.4.2   EMSA analysis 
EMSA  analysis  was  performed  according  to  a  previously  described  method 
(204). Briefly, cells were incubated as indicated in the individual experiments, 
scraped-off,  resuspended  in  200  µl  ice  cold  hypotonic  cell  lysis  buffer  and 
incubated on ice for 10 min. After centrifugation (500 x g, 30 min, 4° C), the 
nucleic pellet was resolved in 100 µl nuclear lysis buffer, incubated on ice for 
20 min, vortexed each 2 min for 10 sec, and pelleted (16000 x g, 5 min, 4° C). 
Supernatants were collected and protein concentration was determined by the 
Lowry method (4.2.3.2). Nuclear protein (10 µg) was incubated for 30 min at 
room  temperature  with  2  µg  poly(dI-dC),  2  µl  buffer  D,  4  µl  buffer  F,  and 
250 fmol 5’-IRDye
®700-labeled oligonucleotide in a final volume of 20 µl. In the 
case  of  competitive  EMSA,  additionally  2500  or  25000  fmol  of  unlabeled 
oligonucleotide  were  added  prior  to  250  fmol  5’-IRDye
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oligonucleotide.  Thereafter,  samples  were  incubated  on  ice  for  5  min.  DNA-
protein complexes were resolved on native 6% polyacrylamide gels at 80 V for 
1  h  and  analyzed  with  the  Odyssey  infrared  imaging  system.  The  gel 
composition is listed in table 2. 
 
          Table 2. Composition of EMSA polyacrylamide gels. 
  6% 
20 x Running buffer  500 µl 
40% acrylamide/bis-acrylamide 
(29%:1.0% w/v) 
1.5 ml 
H2O  8 ml 
10% (w/v) APS  100 µl 
TEMED  20 µl 
 
 
4.2.5  Determination of mRNA contents of cells 
 
For the evaluation of changes in mRNA expression, RNA was isolated, followed 
by reverse transcription and quantitative PCR. 
 
4.2.5.1   RNA isolation 
Cells  were  incubated as  indicated  in  the  individual  experiments, scraped-off, 
resuspended  in  1  ml peqGOLD  RNAPure™  and  incubated for 5 min  at  RT. 
Then,  200  µl  chloroform  were  added,  samples  were  vortexed  thoroughly  for 
15 sec  and  incubated  for  another  10  min  at  RT.  To  separate  the  RNA-
containing water-phase from the phenol-phase and the intermediate lipid-layer 
samples were centrifuged (12000 x g, 5 min, 4° C). After collecting the water-
phase,  RNA  was  precipitated  by  adding  500  µl  isopropanol  followed  by 
incubation for 30 min at RT and centrifugation (16000 x g, 15 min, 4° C). Pellet 
was washed twice in 1 ml 75% ethanol in DEPC-treated H2O by vortexing and 
subsequent centrifugation (16000 x g, 10 min, 4° C). Then, pellet was dried at 
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30 min. RNA content was determined using the NanoDrop
® spectrophotometer 
system, which calculated RNA content according to the fact that at 260 nM an 
OD of 1 is equivalent to 40 µg/ml RNA. Furthermore, quality was checked by 
determining the ratios of OD260/OD280 and OD260/OD230.  
 
 
4.2.5.2   Reverse Transcription 
Reverse Transcription was performed using iScript™ cDNA Synthesis Kits. 1 µg 
total RNA in 15 µl nuclease-free H2O was mixed with 4 µl 5 x reaction buffer 
and 1  µl  iScript™  reverse  transcriptase.  Mixture  was  incubated for  5 min  at 
25° C, 30 min at 42° C and finally 5 min at 85° C to i nactivate the enzyme. The 
resulting cDNA was diluted 1:5 before being used for quantitative PCR.  
 
 
4.2.5.3   Quantitative PCR  
Quantitative  PCR  was  performed  using  ABsolute™  QPCR  SYBR
®  Green 
fluorescein  mix.  Depending  on  the  primers  different  reaction  mixtures  were 
pipetted in 96-well PCR plates. The reaction mixtures are listed in table 3. 
 
 Table 3. Reaction mixtures of quantitative PCR. 
 
Primers from 
biomers 
QuantiTect 
Primer Assay 
cDNA  2 µl  2 µl 
Forward primer (10 pmol/µl)  0.6 µl  - 
Reverse primer (10 pmol/µl)  0.6 µl  - 
Primer assay  -  2 µl 
ABsolute™ QPCR SYBR
® Green  10 µl  10 µl 
H2O  6.8 µl  6 µl 
 
In the case of the reference gene (actin or ribosomal 18S RNA) only 1 µl of 
cDNA was used. After briefly spinning down the plate, it was sealed with optical 
tape.  PCR  was  performed  using  the  MyiQ™  Single  Color  Real-Time  PCR 
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Activation of polymerase  2 min    50° C 
Initial denaturation    15 min  95° C 
Denaturation     15 sec  95° C       
Primer annealing    30 sec  TA° C       45 x 
Elongation      30 sec  72° C 
Final denaturation    1 min    95° C 
Final renaturation    55° C    1 min 
Melting curve    +0.5° C  10 sec 
 
Annealing temperature (TA) was dependent on the used primer pairs. For all 
primer pairs except the ones for human S1P2 and S1P3 TA was 55° C. In the 
case of S1P2 and S1P3 primers TA was 54° C.  
As  SYBR
®  Green  intercalates  into  double-stranded  DNA  molecules, 
fluorescence intensity, which was measured at the end of each elongation step, 
reflected the quantum of PCR products. 
A  melt  curve  was  created  to  show  the  melting  points  of  PCR  products  and 
therefore to confirm the specificity of the reaction. Samples were analyzed using 
the  MyiQ™  1.0  and  Gene  Expression  Macro  1.1  software  with  actin  or 
ribosomal 18S RNA expression as internal control. 
 
 
4.2.6  Genotyping of mice 
 
Tail tips were heated for 20 min at 100° C in 70 µl  genotyping lysis buffer. After 
incubation  for  1  min  on  ice,  70  µl  of  genotyping  neutralization  buffer  were 
added. Non-lysed tissue was sedimented by centrifugation (12000 x g, 15 sec, 
4° C).  Supernatant  containing  genomic  DNA  was  used  f or  PCR  analysis. 
According to the following schemes two different PCRs were performed. 
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Supernatant         2.5 µl 
MgCl2 (25 mM)        5 µl 
dNTPs (10 mM)        1 µl 
Primer P1 (10 pmol/µl)      1 µl 
Primer P2 (10 pmol/µl)      1 µl 
Taq DNA Polymerase (5 U/µl)    2 µl 
PCR Buffer (5 x)        10 µl 
H2O            27.5 µl 
 
Supernatant         2.5 µl 
MgCl2 (25 mM)        5 µl 
dNTPs (10 mM)        1 µl 
Primer F4/80 exon 1 (10 pmol/µl)   1 µl 
Primer F4/80 3.4 (10 pmol/µl)    1 µl 
Primer Cre rev 1        1 µl 
Taq DNA Polymerase (5 U/µl)    2 µl 
PCR Buffer (5 x)        10 µl 
H2O            26.5 µl 
 
PCR was performed according to the following parameters.   
 
Denaturation     1 min    94° C       
Primer annealing    30 sec  TA° C       30 x 
Elongation      1 min    72° C 
Final elongation    5 min    72° C 
 
TA was 50° C for primers P1 and P2 and 63° C for primer s F4/80 exon 1, F4/80 
3.4 and Cre rev 1. After the addition of 10 µl DNA loading dye, PCR products 
were resolved on agarose gels (2% in 0.5 x TBE) for 2 h at 120 V. Gels were 
stained for 15 min in an ethidium bromide bath (1 µg/ml) and DNA fragments 
were detected using an UV light gel documentation system.   
The  PCR,  in  which  primer  pairs  P1  and  P2  were  used,  amplified  a  200  bp 
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the S1P1
loxP allele. The second PCR amplified a 100 bp fragment for the F4/80 
wild-type allele and a 145 bp fragment for the Cre allele.     
  
 
4.2.7  Quantification of VEGF release from macrophages 
 
5  x  10
6  macrophages  were  incubated  in  3-cm  dishes  with  AC-CM  for  2  h, 
washed twice with PBS, and incubated for another 16-h period. Supernatants 
were harvested by centrifugation (16000 x g, 10 min, 4° C). Measurement of 
VEGF  release  from  macrophages  was  performed  using  human  VEGF 
Cytometric  Bead  Array  Flex  Sets.  Briefly,  50  µl  of  the  supernatant  were 
incubated  with  beads  coated  with  antibodies  against  VEGF  and  a 
phycoerythrin-labeled detection reagent for 3 h. Samples were analyzed with 
the FACSCanto™ flow cytometer and quantitated using the FCAP Array 1.0.1 
software.  
 
 
4.2.8  Amplification of plasmids in bacteria   
 
Before  being  used  for  transfection  of  macrophages,  plasmids  had  to  be 
amplified in bacteria. 
 
4.2.8.1   Transformation of bacteria by heat shock 
Plasmids  were  transformed  into  supercompetent  bacteria  using  heat  shock 
method.  Therefore,  50  µl  of  bacteria  stocks  were  thawed  on  ice,  100  ng  of 
plasmid DNA were added and mixed gently. After incubation on ice for 30 min, 
heat shock (45 sec, 42° C) was performed and bacteri a were incubated on ice 
for  another  2  min.  Then,  400  µl  of  SOC  medium  were  added,  followed  by 
incubation  for  60  min  at  37° C  with  shaking  (250  rpm ).  For  the  selection  of 
plasmid-carrying clones, 200 µl of the cultures were inoculated on ampicillin-
containing (100 µg/ml) LB agar plates and incubated overnight at 37° C.   
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4.2.8.2   Bacteria culture  
For the preparation of plasmids, a single colony from the LB agar plate was 
picked, transferred into 3 ml LB medium supplemented with 100 µg/ml ampicillin 
and cultured overnight at 37° C with shaking (250 rp m). Then, this pre-culture 
was transferred into 200 ml ampicillin-containing (100 µg/ml) LB medium and 
again grown overnight under the same conditions.  
 
 
4.2.8.3   Preparation of plasmid DNA  
The HiSpeed
® Plasmid Maxi Kit was used to isolate plasmids from bacteria. The 
procedure  followed  the  protocol  of  the  manufacturer.  DNA  content  was 
measured using the spectrophotometer NanoDrop
® ND-1000. 
 
 
4.2.9  Site-directed mutagenesis 
 
Using  the  online  transcriptional  regulatory  element  database  CSH  and  the 
online tool TFSearch potential STAT binding sites in the human HO-1 promoter 
(STAT response elements [STATx]) were identified. 
A  point  mutation  of  the  putative  STAT  binding  site  at  position  -2361  bp  to 
-2369 bp  within  the  human  HO-1  promoter,  to  impair  STAT3  binding,  was 
generated  using  the  QuikChange
®  II  XL  Site-Directed  Mutagenesis  Kit.  The 
phHOLUC(-2782)  construct  served  as  a  template.  Primers  were  designed 
according to the manufacturer’s instructions and are listed in 4.1.11. 10 ng of 
the template DNA, 125 ng of each primer, 5 µl 10 x reaction buffer, 1 µl dNTP 
mix, 3 µl QuikSolution™ reagent and 1 µl PfuUltra HF DNA polymerase were 
mixed and filled-up with H2O to 50 µl. PCR was performed according to the 
following parameters. 
 
Initial denaturation    1 min    95° C 
Denaturation     50 sec  95° C 
Primer annealing    50 sec  60° C      18 x 
Elongation      15 min  68° C 
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Thereafter, the nonmutated parental DNA template was digested by incubation 
with 10 U Dpn I for 1 h at 37° C. Then, mutated plas mids were transfected into 
XL-10-Gold
Ò  ultracompetent  bacteria  using  the  heat  shock  method  (4.2.8.1). 
After the selection of positive clones the plasmid DNA was extracted using the 
HiSpeed
® Plasmid Maxi Kit. Correct sequence of the generated vectors was 
confirmed by sequencing, which was performed by AGOWA GmbH (Berlin). 
 
 
4.2.10   Reporter assay 
 
After individual incubations, medium was removed from 12-well plates, 100 µl 
H2O/well was added followed by subsequent storage at -80° C. After at least 
30 min  of  freezing,  plates  were  thawed  by  shaking  for  15  min  at  RT  and 
subsequent centrifugation (3220 x g, 10 min, 4° C). Then, 50 µl of each well 
were transferred into two different 1.5-ml reaction tubes. The addition of 50 µl 
2 x firefly lysis buffer to the first tube and 50 µl 2 x passive lysis buffer to the 
second tube was followed by vortexing. 20 µl of each sample was pipetted in 
duplicates  into  white  96-well  plates.  In  the  Mithras  LB  940  multilabel  reader 
50 µl  of  firefly  assay  reagent  or  Renilla  assay  reagent  were  automatically 
added,  the  plate  was  shaken  for  2  s  and  luminescence  was  measured.  To 
control  transfection  efficiency  as  well  as  cell  number  of  each  well,  firefly 
luciferase activity was normalized to Renilla luciferase activity.  
 
 
4.2.11   Microscopy 
 
For immunofluorescence analysis, primary human macrophages were seeded 
in  10-cm  dishes  and  differentiated  for  7  days.  Then,  macrophages  were 
removed from dishes as described in section 4.2.2.2. Slides were sterilized with 
75% ethanol and placed in fresh 10-cm dishes, in which macrophages were 
seeded once again. After incubation for 2 days macrophages were used for 
experiments.  Following  individual  stimulations,  macrophages  were  fixed  in 
4% PFA for 1 h. Macrophages were permeabilized by incubation in 1% Triton X-
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staining was blocked by incubation with 30% FCS (in 1% Triton X-100) for 1 h. 
S1P1 antibody was incubated in PBS overnight at 4° C. Fo llowing three washes 
with PBS, Alexa Fluor
® 546-labeled goat anti-mouse antibody was incubated in 
PBS for 2 h in the dark. Nuclei were labeled by DAPI staining (20 ng/ml in PBS) 
for  20  min.  For  isotype  staining,  cells  were  only  stained  with  the  secondary 
antibody and DAPI. After three additional washed with PBS, slides were dabbed 
with VECTASHIELD
® and covered with cover slips.  
For scratch assays, 10% of one buffy coat monocyte preparation were seeded 
in 4 wells of one 12-well plate. Primary murine macrophages were seeded as 
described in section 4.2.1.3. Scratch assay was performed after differentiation 
of  primary  human  monocytes  for  7  days  or  after  culture  of  primary  murine 
macrophages for 3-5 days. Cells were starved by cultivation in RPMI without 
serum  for  8  h  (primary  human  macrophages)  or  16  h  (primary  murine 
macrophages). Then, scratch was drawn in the middle of each well using a 
small  pipette  tip.  This  was  followed  by  twice  washing  with  PBS  to  remove 
detached cells. Then AC-CM was added and scratch width was microscopically 
documented. In the case of primary human macrophages, macrophages were 
washed three times with PBS after 1 h of incubation with AC-CM and 1 µM VPC 
23019, an S1P1/3 antagonist (205), was added. Ring-shaped stickers served to 
recover scratches after incubation periods, which were 9 h for primary murine 
macrophages or 16 h for primary human macrophages, respectively.     
The immunofluorescence of fixed cells or the phase contrast of living cells was 
visualized with the fluorescence microscope Axiovert 200M together with the 
ApoTome unit. 
For  scratch  asssays  the  area  between  the  two  sides  of  the  scratch  was 
calculated using AxioVision Rel. 4.4 software. 
 
 
4.2.12   Statistical analysis 
 
Each experiment was performed at least three times. For Western, EMSA and 
microscopy analysis one representative experiment is displayed. p-values were 
calculated  using  the  paired  Student’s  t  test  and  considered  significant  at 
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5  RESULTS    
 
5.1  Apoptotic  cell  supernatants  provoke  a  biphasic 
upregulation of HO-1  
 
My  studies  originated  from  a  report  showing  that  FTY720,  a  sphingosine 
analog, which can be phosphorylated by SphK2 to act similar to S1P (206), 
enhanced  HO-1  expression  (207).  Furthermore,  it  was  proven  that  S1P  is 
released from AC (35) and provides anti-apoptotic as well as anti-inflammatory 
potential similar to the effects seen with CO (discussed in 3.5.4). Therefore, I 
first addressed whether HO-1 is induced in primary human macrophages after 
treatment with AC supernatants (AC-CM).  
 
 
5.1.1  HO-1 is upregulated in a time-dependent manner 
 
In  a  first  set  of  experiments,  HO-1  protein  expression  in  primary  human 
macrophages  was  analyzed  following  their  exposure  to  AC-CM.  HO-1 
expression showed a biphasic response. While the first peak was noticed after 
6 h, a second peak was observed after 24 h of incubation with AC-CM (Figure 
8).  
 
 
 
Figure 8. Induction of HO-1 by AC-CM in macrophages. Western analysis of HO-1 expression 
in primary human macrophages following treatment with AC-CM for times as indicated. The 
Western blot is representative for three individual experiments. 
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5.1.2  HO-1 upregulation is mediated by autocrine and paracrine signaling  
 
The biphasic expression scheme of HO-1 led to the assumption that the second 
peak of HO-1 expression might be mediated by an autocrine factor, which was 
released  by  macrophages  following  treatment  with  AC-CM.  To  verify  this 
hypothesis, supernatants from macrophages (MF-CM), which were previously 
stimulated with AC-CM, were harvested and MF-CM was transferred to fresh, 
resting  macrophages.  Indeed,  not  only  AC-CM  but  also  MF-CM  enhanced 
HO-1  protein  expression  in  primary  human  macrophages  (Figures  8  and  9). 
Pronounced  HO-1  expression  in  response  to  MF-CM  was  detected  after 
12-18 h,  which  corresponded  to  the  second  peak  of  HO-1  expression  in 
response to AC-CM, seen after 24 h. Thus, paracrine signaling by AC as well as 
autocrine signaling of macrophages contributed to the induction of HO-1. 
 
 
 
Figure 9. Induction of HO-1 by MF-CM in macrophages. Western analysis of HO-1 expression 
in  primary  human  macrophages  after  incubation  with  MF-CM  for  times  as  indicated.  One 
representative Western blot out of three individual experiments is displayed. 
 
 
5.1.3  HO-1 induction is specifically mediated by AC but not by VC or NC   
 
Importantly, HO-1 expression was only seen in response to AC-CM, but was not 
elicited by conditioned medium from necrotic cells (NC-CM) or viable cells (VC-
CM) (Figure 10). Consequently, HO-1 expression can be attributed to a factor, 
which is uniquely produced by AC. The production of this factor may need a 
complex  release  mechanism,  as  it  is  not  released  as  a  result  of  membrane 
rupture, which is observed in NC.  
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Figure 10. Induction of HO-1 by different forms of CM in macrophages. HO-1 expression in 
primary human macrophages treated with CM of AC, NC or VC for 24 h. The Western blot is 
representative for three individual experiments. 
 
 
5.1.4  AC-CM enhances transcription of the HO-1 promoter  
 
The  induction  of  HO-1  by  MF-CM  after  18  h  was  further  corroborated  by 
reporter assays. Using the luciferase-coupled promoter constructs phHOLUC40 
as well as phHOLUC(-2782), a significant induction of luciferase activity was 
noticed after treatment with MF-CM for 18 h (Figure 11). However, no activity 
was observed with the shorter luciferase construct phHOLUC(-1976). Results 
so far indicate that AC supernatants not only caused HO-1 protein expression, 
but also enhanced the transcription of the HO-1 promoter.  
 
 
 
Figure 11. Induction of HO-1 promoter by MF-CM in macrophages. HO-1 promoter activity in 
primary human macrophages after transfection of individual phHOLUC reporter constructs and 
stimulation with MF-CM for 18 h. Firefly luciferase activity was normalized to Renilla luciferase 
activity.  Data  are  means  ±  SEM  of  at  least  four  independent  experiments.  Asterisks  mark 
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5.1.5  p38 MAPK and Jak pathways are involved in HO-1 expression 
 
Next,  I  investigated  signal  transduction  pathways  contributing  to  HO-1 
expression.  Therefore,  macrophages  were  pre-incubated  with  inhibitors  of 
pathways known to be associated with HO-1 induction, before stimulating them 
with AC-CM. The early expression of HO-1, after 6-h treatment with AC-CM, 
was reversed by SB203580, an inhibitor of p38 MAPK (Figure 12 A). The late-
phase  HO-1  expression  at  24 h  was  partially  attenuated  by  inhibiting  Janus 
kinase signaling (Figure 12 B). Thus, the early HO-1 induction in response to an 
AC-CM-derived soluble factor was p38-mediated, whereas the late and second 
phase of HO-1 expression was facilitated by an autocrine factor, signaling via 
the Jak pathway.  
 
 
 
Figure 12. Inhibition of AC-CM-induced HO-1 expression in macrophages. (A) HO-1 expression 
in primary human macrophages after incubation with AC-CM for 6 h in the presence/absence of 
5 µM SB203580. (B) Treatment of macrophages with AC-CM for 24 h with 1 µM Jak inhibitor I 
being present. Western blots are representative for at least three individual experiments.  
 
 
5.2  Apoptotic  cell-derived  S1P  is  crucial  in  provoking  HO-1 
induction  
 
As mentioned in section 5.1, my hypothesis was that S1P derived from AC-CM 
was responsible for the enhanced HO-1 expression in macrophages.  
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5.2.1  Apoptotic cell-derived S1P induces HO-1 protein expression   
 
In a first approach primary human macrophages were stimulated with authentic 
S1P for 24 h (Figure 13). S1P at 100 nM and 1 µM as well as AC-CM facilitated 
HO-1 protein expression. DMS, an inhibitor of sphingosine kinases, was used to 
block their activity in Jurkat cells during the generation of AC-CM and thus to 
validate the contribution of S1P in AC-CM. AC-CM generated in the presence of 
DMS failed in inducing HO-1 expression in macrophages.   
 
 
 
Figure  13.  Apoptotic  cell-derived  S1P  mediates  HO-1  protein  induction  in  macrophages. 
Western analysis of HO-1 expression in primary human macrophages treated with AC-CM, S1P 
or  DMS-AC-CM  for  24  h.  20  µM  DMS  were  used  to  block  the  release  of  S1P  into  the 
supernatant  of  apoptotic  cells  (DMS-AC-CM).  One  representative  Western  blot  of  three 
individual experiments is outlined.  
 
 
5.2.2  Authentic S1P enhances transcription of the HO-1 promoter   
 
S1P,  supplied  for  24  h,  also  induced  luciferase  reporter  activity  (Figure  14), 
which further supported the data obtained at the protein level. Like AC-CM, S1P 
induced  phHOLUC40  and  phHOLUC(-2782)  HO-1  reporter  activity,  while 
phHOLUC(-1976) HO-1 reporter activity was not affected.  
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Figure 14. S1P induces HO-1 promoter activation in macrophages. HO-1 promoter activity of 
corresponding  phHOLUC  reporter  constructs  in  primary  human  macrophages  treated  with 
100 nM  S1P  for  24  h.  Firefly  luciferase  activity  normalized  to  Renilla  luciferase  activity  is 
displayed. Data are means ± SEM of at least three independent experiments. Asterisks mark 
statistically significant differences (p £ 0.05).   
 
 
5.2.3  The induction of HO-1 is mediated via S1P1 
 
Activation  of  S1P1  was  reported  to  limit  the  expression  of  pro-inflammatory 
cytokines  (116)  and  to  protect  macrophages  from  apoptosis  induced  by  the 
combination of TNFa and cycloheximide (35). As it is widely accepted that the 
enhanced expression of HO-1 is accompanied by anti-inflammatory and anti-
apoptotic  effects,  I  suggested  that  S1P1  could  play  an  important  role  in  the 
induction of HO-1 in my system. Therefore, knockdown of S1P1 was performed 
to asses its role in HO-1 induction by AC-CM. Transfection of macrophages with 
non-targeting siRNA allowed the induction of HO-1 expression by AC-CM after 
6 h, whereas knockdown of S1P1 significantly reduced the HO-1 amount (Figure 
15). Interestingly, I noticed that AC-CM enhanced S1P1 expression in primary 
human macrophages, an effect suppressed by siRNA directed against S1P1. I 
will elaborate on this effect in section 5.6. 
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Figure 15. S1P1 mediates HO-1 protein induction in macropages. Primary human macrophages 
were transfected with non-targeting siRNA or siRNA against S1P1. Western analysis of S1P1 
and HO-1 was performed after 6-h treatments with AC-CM. The Western blot is representative 
for three individual experiments.  
 
 
5.3  STAT1 and STAT3 provoke autocrine transcription of the 
HO-1 gene  
 
As shown in figure 12 B, the induction of HO-1 after 24 h was dependent on Jak 
signaling.  Considering  that  HO-1  induction  at  24  h  was  facilitated  by  an 
autocrine factor (Figure 9), I wanted to discern whether the release or the action 
of  the  putative  autocrine  factor  would  be  Jak-dependent.  Therefore,  using 
STAT1  and  STAT3  inhibitors,  signaling  downstream  of  Janus  kinases  was 
analyzed.  
 
 
5.3.1  The autocrine factor is released in a STAT1-dependent way and acts 
via STAT1 and STAT3 
 
To  attenuate  the  release  of  autocrine  mediators,  macrophages  were  pre-
incubated for 1 h with either fludarabine, a specific inhibitor of STAT1 (208), or 
STA-21, a specific STAT3 inhibitor (209), prior to the addition of AC-CM. After 
incubation  with  AC-CM  for  2 h, macrophages  were  washed  twice  with  PBS, 
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addition of inhibitors. Thereupon, MФ-CM was harvested from these cells and 
added to fresh, unstimulated macrophages for 18 h. Inhibition of STAT1 during 
the production of MF-CM with fludarabine eliminated its potential to upregulate 
HO-1,  indicating  that  the  production  of  the  autocrine  mediator  was  STAT1-
dependent (Figure 16 A, lane 3). In contrast, blocking STAT3 by STA-21 during 
the production of MF-CM did not diminish HO-1 expression (Figure 16 B, lane 
3).  Interestingly,  inhibition  of  STAT1  or  STAT3  attenuated  the  expression  of 
HO-1 in response to MF-CM (Figure 16 A and B, lane 4), suggesting that the 
autocrine factor demands active STAT1 and STAT3 for signaling.  
 
 
 
Figure  16.  STAT1  and  STAT3  signaling  are  involved  in  HO-1  promoter  activation  in 
macrophages. Primary human macrophages were incubated for 6 h with AC-CM with or without 
the addition of (A) 20 µM fludarabine or (B) 10 µM STA-21. MF-CM was harvested and added 
to fresh macrophages for 18 h with or without the addition of fludarabine (A) or STA-21 (B). 
Western blots are representative for at least three individual experiments. 
 
 
5.3.2  STAT binding sites located within the human HO-1 promoter 
 
These initial data suggested a role of STAT1 and STAT3 in late-phase (24 h) 
HO-1 expression by AC-CM. Therefore, I screened the human HO-1 promoter 
for potential STAT binding sites (Figure 17). Luciferase activity after treatment 
with  MF-CM  for  18  h  was  not  induced  following  transfection  of 
phHOLUC(-1976)  into  macrophages  (Figure  11),  thus  excluding  the  three 
putative STAT binding sites located within this promoter construct as candidates 
involved in enhanced HO-1 transcription. 
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Figure  17.  Putative  STAT  binding  sites  in  the  human  HO-1  promoter.  The  human  HO-1 
promoter contains five STAT binding sites located within the sequence 2782 bp upstream from 
the  transcription  start  including  three  STAT  binding  sites  withing  the  sequence  -1976  bp  to 
+1 bp.   
 
 
5.3.3  Identification  of  the  STAT  binding  site  responsible  for  HO-1 
induction     
 
Concerning the two remaining potentially critical STAT binding sites in the HO-1 
promoter, only oligonucleotides resembling the STAT binding site at -2361 bp to 
-2369 bp, but not the ones containing the STAT binding site at -2436 bp to 
-2444  bp  recruited  transcription  factors  in  EMSA  analysis  (Figure  18  A). 
Supporting  the  notion  that  HO-1  induction by  the  autocrine factor  present  in 
MF-CM was inhibited by fludarabine and/or STA-21 (Figure 16 A and B), EMSA 
analysis  revealed  that  transcription  factor  binding  to  the  oligonucleotides 
spanning the STAT binding site at -2361 bp to -2369 bp was slightly reduced 
when macrophages where incubated with fludarabine (Figure 18 A). Stronger 
inhibition was observed when macrophages were treated with STA-21 prior to 
MF-CM stimulation, whereas the combined application of both STAT inhibitors 
reduced transcription factor binding most efficiently. These observations imply 
that  STAT1/STAT3  heterodimer  binding  to  the  putative  STAT  binding  site 
located  at  -2361 bp  to  -2369 bp  at the  human  HO-1 promoter affects  HO-1 
induction following treatment with MF-CM.  
To  reinforce  these  results,  I  performed  competitive  EMSA  analysis  with 
unlabeled  oligonucleotides  specific  for  STAT1  or  STAT3  or  with 
oligonucleotides  for  the  putative  STAT  binding  site  at  -2361  bp  to  -2369  bp 
containing  a  point  mutation  for  STAT3  (Figure  18  B).  STAT  binding  to  the 
oligonucleotides containing the STAT binding site at -2361 bp to -2369 bp was 
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oligonucleotides. In contrast, when using oligonucleotides with the STAT3 point 
mutation, STAT binding was not impaired.  
 
 
 
Figure 18. STAT1/STAT3 heterodimers mediate HO-1 promoter activation in macrophages. (A) 
EMSA  analysis  in  primary  human  macrophages  using  250  fmol  of  the  oligonucleotides 
resembling the putative STAT binding site at -2361 bp to -2369 bp of the human HO-1 promoter 
in the presence/absence of 20 µM fludarabine and/or 10 µM STA-21. (B) Competitive EMSA 
analysis using 2.5 pM or 25 pM of unlabeled oligonucleotides specific for STAT1, STAT3 or 
oligonucleotides for the putative STAT binding site at -2361 bp to -2369 bp, which contained a 
STAT3 point mutation (Ptm), in addition. One representative EMSA out of three is displayed.   
 
In addition, reporter assays  were performed in primary human macrophages 
with  the  construct  phHOLUC(-2782ptm).  This  construct  contained  a  point 
mutation  within  the  STAT  binding  site  at  -2361  bp  to  -2369  bp  to  eliminate 
STAT3  binding  (Figure  19).  Transfection  of  this  construct  into  macrophages 
confirmed the results obtained by EMSA analysis, as luciferase activity elicited 
by  MF-CM  was  significantly  lower  compared  with  transfection  of  the  non-
mutated  phHOLUC(-2782).  Thus,  the  STAT  binding  site  located  at  position 
-2361  bp  to  -2369  bp  of  the  human  HO-1  promoter  can  be  considered  the 
critical binding site responsible for the induction of HO-1 after treatment with 
AC-CM.  
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Figure 19. The STAT binding site at -2361 bp to -2369 bp is responsible for HO-1 promoter 
activation in macrophages. HO-1 promoter activity in primary human macrophages following 
transfection of the corresponding phHOLUC promoter constructs and stimulation with MF-CM 
for 18 h. Histograms show firefly luciferase activity normalized to Renilla luciferase activity. Data 
are  means  ±  SEM  of  at  least  four  independent  experiments.  Asterisks  mark  statistically 
significant differences (p £ 0.05).  
 
 
5.4  Late-phase  HO-1  induction  in  macrophages  requires 
autocrine VEGFA signaling 
 
5.4.1  The autocrine induction of HO-1 by MF F F F-CM is mediated by a protein 
factor   
 
To elucidate which factor is released by macrophages following treatment with 
AC-CM to induce HO-1 in an autocrine way, I first degraded proteins in MF-CM 
with proteinase K digestion. MF-CM, deprived by functional proteins, revealed a 
significantly  lower  ability  to  express  HO-1  compared  with  untreated  MF-CM 
(Figure 20), implying that the autocrine factor might be a protein.  
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Figure  20.  A  protein  factor  is  important  for  the  late-phase  induction  of  HO-1  protein  in 
macrophages. Primary human macrophages were controls or treated with either MF-CM or de-
proteinated MF-CM (50 µg/ml proteinase K) for 18 h. One representative Western blot out of 
seven is displayed. The graph shows the densitometric analysis. Asterisks indicate statistically 
significant differences (*p £ 0.05 and **p £ 0.01). 
 
 
5.4.2  VEGF secretion by macrophages is S1P- and STAT1-dependent  
 
My previous results (Figure 16 A) suggested that the release of the autocrine 
factor mediating HO-1 induction was STAT1-dependent. This corresponds to 
the observations of Funamoto and colleagues, who identified VEGF as a target 
gene  of  STAT1  signaling  in  cardiac  myocytes  (210).  Furthermore,  VEGFA 
secretion from mouse mammary epithelial cells after phagocytosis of AC was 
previously demonstrated (211) and signaling of VEGF in chronic lymphocytic 
leukaemia B cells enhanced STAT3 actions (212). These observations match 
my  data,  indicating  that  the  autocrine  protein  factor  in  MF-CM  activated 
STAT1/STAT3 (Figure 16 A and B). Finally, VEGF induced HO-1 in a model of 
hyperoxic acute lung injury (213). Therefore, I proposed VEGF as a candidate 
being  responsible  for  the  late  phase  of  HO-1  expression  observed  in  my 
system.  
Indeed, VEGF mRNA was significantly elevated in macrophages treated with 
AC-CM for 1 h, compared with controls. Augmentation of VEGF mRNA was 5 Results                                                                                                            77                                                                                                                                                                                            
blocked  when  macrophages  were  pretreated  with  fludarabine  (Figure  21  A). 
Additionally,  I  quantified  the  release  of  VEGF  into  supernatants  of  AC-CM-
treated macrophages by FACS analysis using human VEGF Cytometric Bead 
Array  Flex  Sets  (Figure  21  B).  AC-CM-stimulated  macrophages  secreted 
significant amounts of VEGF protein. Accompanying experiments revealed that 
100 nM authentic S1P, added to macrophages for 1 h, enhanced VEGF mRNA 
expression, consequently supporting the notion that S1P in AC-CM may induce 
VEGF (Figure 21 C). Since HO-1 as well as VEGF expression were induced by 
S1P (Figures 13 and 21 C), an induction of HO-1 by autocrine VEGF signaling 
in primary human macrophages seemed likely. 
 
 
 
Figure  21.  VEGF  induction  in  macrophages  is  dependent  on  S1P  and  STAT  signaling.  (A) 
VEGF mRNA expression after stimulation of primary human macrophages with AC-CM or AC-
CM together with 20 µM fludarabine for 1 h. (B) Quantitation of VEGF secretion by control or 
AC-CM-stimulated  (18  h)  macrophages.  (C)  VEGF  mRNA  expression  in  control  or  S1P-
stimulated (100 nM, 1 h) macrophages. Graphs display mean values ± SEM of at least four 
independent experiments and asterisks indicate statistically significant differences *p £ 0.05 and 
**p £ 0.01. 
 
 
5.4.3  VEGFA is the crucial factor of MF F F F-CM provoking HO-1 induction 
 
To  further  scrutinize  this  hypothesis,  VEGF  was  knocked  down  in  primary 
human macrophages prior to their incubation with AC-CM (Figure 22 A). VEGF 
mRNA expression was induced in macrophages following incubation with AC-
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Finally, to prove that VEGF was the autocrine factor secreted by macrophages, 
I  analyzed  the  expression  of  HO-1  protein  in  macrophages,  which  were 
incubated  with  MF-CM  generated  from  VEGF  knockdown  or  siControl 
transfected  macrophages.  When  macrophages  were  transfected  with  non-
targeting siRNA and incubated with AC-CM, MF-CM derived from these cells 
induced HO-1 in fresh, unstimulated cells. However, HO-1 was not induced with 
MF-CM  from  VEGFA  knockdown  macrophages  (Figure  22  B).  Thus,  these 
experiments suggest that VEGF mediated the autocrine induction of HO-1 after 
stimulation with AC-CM.  
 
 
 
Figure 22. HO-1 expression in macrophages by autocrine VEGFA signaling. Primary human 
macrophages were transfected with non-targeting siRNA or siRNA against VEGFA. (A) VEGF 
mRNA expression in control or AC-CM-treated macrophages after 6 h. Graph displays mean 
values  ±  SEM  of  six  independent  experiments.  Asterisks  indicate  statistically  significant 
differences (p £ 0.05). (B) Western analysis of HO-1 expression (18 h) following treatment with 
MF-CM. One representative blot out of three is displayed.  
 
 
5.5  HO-1  affects  anti-inflammatory  and  anti-apoptotic 
pathways in macrophages  
 
HO-1  is  well-known  for  its  anti-apoptotic  and  anti-inflammatory  actions  (140, 
167, 214). As shown recently, S1P from AC-CM induced Bcl-2 and Bcl-XL in 
macrophages  (35),  I  addressed  the  question  whether  the  induction  of  Bcl-2 
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5.5.1  HO-1 affects the expression of Bcl-2, Bcl-XL and Adora A2A 
 
HO-1  in  primary  human  macrophages  was  knocked  down  by  using  siRNA 
technology. Transfection with siRNA directed against HO-1 efficiently blocked 
the mRNA increase of HO-1 after treatment with AC-CM for 9 h (Figure 23).  
 
 
 
Figure  23.  Downregulation  of  HO-1  in macrophages  by  siRNA  transfection.  Primary  human 
macrophages  were controls or transfected with siRNA against HO-1 or non-targeting siRNA 
followed  by  treatment  with  AC-CM  for  9  h.  Graph  displays  mean  values  ±  SEM  of  16 
independent experiments. Asterisks indicate statistically significant differences (p £ 0.001). 
 
AC-CM induced Bcl-2 and Bcl-XL mRNA in macrophages transfected with non-
targeting siRNA, whereas their upregulation was significantly diminished when 
macrophages were transfected with siRNA against HO-1 (Figure 24 A). This 
suggests  a  role  of  HO-1  in  contributing  to  the  anti-apoptotic  phenotype  of 
macrophages elicited by AC-CM (35).  
To  examine  whether  the  increased  HO-1  expression  also  conveyed  anti-
inflammatory properties in my system, I analyzed the expression of the three 
markers  Adora  A2A,  IDO  and  HLA-DMB,  which  are  generally  linked  to  anti-
inflammatory responses in macrophages. While the expression of Adora A2A 
was enhanced in control macrophages incubated with AC-CM, knockdown of 
HO-1 prevented this increase (Figure 24 B). However, there was no correlation 
between the amount of HO-1 and the expression of either IDO or HLA-DMB 
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AC-CM  in  macrophages  either  transfected  with  non-targeting  siRNA  or  with 
siRNA directed against HO-1 (Figure 24 B). In contrast, HLA-DMB expression 
was  decreased  following  stimulation  with  AC-CM,  which  was  unaffected  by 
knockdown of HO-1 (Figure 24 C). 
 
 
 
Figure 24. Regulation of Bcl-2, Bcl-XL, Adora A2A, IDO and HLA-DMB mRNA levels by HO-1 in 
macrophages.  Primary  human  macrophages  remained  as  controls  or  were  transfected  with 
siRNA against HO-1 or non-targeting siRNA. Graphs indicate mRNA expression of Bcl-2, Bcl-XL 
(A), Adora A2A, IDO (B) and HLA-DMB (C) in macrophages following incubations with AC-CM 
for  9  h.  Data  are mean  values  ±  SEM  of  at  least  five  independent  experiments.  Significant 
differences in mRNA expression are marked by *p £ 0.05, **p £ 0.01, and ***p £ 0.001 or were 
not significant (NS). 
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In addition, I examined whether HO-1 also affected protein expression of Bcl-XL 
and  Adora  A2A. Therefore,  macrophages  were  transfected  with  non-targeting 
siRNA or HO-1-specific siRNA and incubated with AC-CM for 16 h. Both, Bcl-XL 
and  Adora  A2A,  were  significantly  induced  by  AC-CM  in  macrophages 
transfected  with  non-targeting  siRNA,  whereas  their  expression  remained 
equivalent  to  controls  in  macrophages  with  siRNA-mediated  knockdown  of 
HO-1 (Figure 25).  
 
 
 
Figure 25. Regulation of Bcl-XL and Adora A2A protein levels by HO-1 in macrophages. Primary 
human macrophages were controls or transfected with siRNA against HO-1 or non-targeting 
siRNA.  Western  analysis  of  HO-1,  Bcl-XL  and  Adora  A2A  expression  in  macrophages  after 
stimulation with AC-CM for 16 h. One representative Western blot out of three is shown. 
 
 
5.5.2  Impact of NO, bilirubin and CO on Adora A2A expression  
 
In inflammatory macrophages, HO-1 is induced as a response to LPS-induced 
NO  production  to  initiate  an  anti-inflammatory  negative  feedback  loop  (215). 
Thus, I investigated whether NO reproduced HO-1-depedent effects on gene 
expression in my system. Indeed, Deta-NO induced Adora A2A. However, this 
induction was less pronounced compared with AC-CM (Figures 24 B and 26). 
To determine which product of the HO-1-catalyzed reaction mediated Adora A2A 
induction, bilirubin and the CO-releasing molecule CORM-2 were used. Both 
agents significantly elevated Adora A2A mRNA expression (Figure 26), although 
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inactivated, i.e. decomposed product of CORM-2 (iCORM-2) exerted no effect 
(Figure 26).  
 
 
 
Figure 26.  Adora  A2A mRNA  expression in macrophages following treatment  with Deta-NO, 
bilirubin or CORM-2. Primary human macrophages were incubated with 500 µM Deta-NO for  
9 h, 10 µM bilirubin for 1 h or 100 µM CORM-2 for 24 h. Graphs display mean values ± SEM of 
at least three independent experiments. Significant differences in mRNA expression are marked 
by asterisks (p £ 0.05). 
 
 
5.6  Impact of AC supernatants on S1P receptor expression 
 
Investigating  the  dependence  of  HO-1  induction  on  S1P1  signaling,  I 
unexpectedly  observed  that  also  S1P1  was  upregulated  in  primary  human 
macrophage following treatment with AC-CM (Figure 15). 
 
5.6.1  AC supernatants provoke upregulation of S1P1 and S1P3 mRNA  
 
As  S1P1-3  are  the  most  important  S1P  receptors  in  myeloid  cells  (115),  I 
investigated  the  expression  schemes  of  these  receptor  isoforms  in  primary 
human macrophages in response to AC-CM. S1P1 and S1P3 showed a time-
dependent mRNA induction pattern being most prominent after incubation for 
3 h.  However,  S1P2  mRNA  expression  was  unaffected  (Figure  27).  As  I 
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S1P3 in primary human macrophages, I focussed on the investigation of S1P1 in 
the following.    
 
 
 
Figure 27. S1P1, S1P2 and S1P3 mRNA expression in macrophages after treatment with AC-
CM. Primary human macrophages were incubated with AC-CM for 1 h or 3 h, respectively. 
Graphs  display  mean  values  ±  SEM  of  at  least  five  independent  experiments.  Significant 
differences in mRNA expression are marked by *p £ 0.05 and ** p £ 0.01. 
   
 
5.6.2  Induction of S1P1 protein expression by AC supernatants 
 
Treatment  of  primary  human  macrophages  with  AC-CM  resulted  in  a  time-
dependent induction of S1P1 protein expression reaching a maximum after 6 h 
(Figure 28).    
 
 
 
Figure 28. Induction of S1P1 protein expression in macrophages following treatment with AC-
CM. Western analysis of S1P1 expression after incubations of primary human macrophages 
with  AC-CM  for  times  as  indicated.  The  Western  blot  is  representative  for  three  individual 
experiments.  
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5.7  Alternative  macrophage  activating  factors  upregulate 
S1P1 mRNA  
 
As  I  observed  that  macrophages  were  alternatively  activated  following 
incubation with supernatants from AC, I asked whether the induction of S1P1 
can  specifically  be  attributed  to  alternative  macrophage  inducing  factors. 
Therefore, primary human macrophages were treated with LPS or INF-g, which 
induce classical activation, or with IL-4 or IL-10 to provoke alternative activation, 
for 3 h. While incubation with IL-4 or IL-10 significantly induced S1P1 mRNA 
expression,  LPS  or  IFN-g  treatment  exhibited  no  influence  on  S1P1  mRNA 
levels (Figure 29). However, the induction of S1P1 was more pronounced after 
AC-CM  compared  to  IL-4  or  IL-10  (Figures  27  and  29).  Interestingly,  also 
authentic S1P showed no effect on S1P1 mRNA expression.    
 
 
 
Figure 29. Induction of S1P1 mRNA expression in macrophages by alternative macrophage 
activating  stimuli.  Primary  human  macrophages  were  treated  for  3  h  with  10  ng/ml  IL-4, 
20 ng/ml IL-10, 1 µg/ml LPS, 100 U/ml IFN-g or 100 nM S1P. Graphs show mean values ± SEM 
of five independent experiments. Significant differences in mRNA expression are marked by 
asterisks (p £ 0.05).     
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5.8  Krüppel-like  factor  is  a  potential  transcription  factor 
mediating S1P1 transcription in response to AC supernatants 
 
To corroborate the induction of S1P1 by AC-CM and to identify the transcription 
factors mediating S1P1 induction, reporter assays were performed in primary 
human macrophages. S1P1 promoter contructs were a kind gift from the group 
of  Jianzhu  Chen  (123).  However,  these  contructs  contained  the  murine 
promoter instead of the human promoter.  
 
 
5.8.1  Transrciption factor binding sites located on the sequence -1000 bp 
to -1300 bp on the murine promoter provoke induction of S1P1 luciferase 
activity 
 
After  transfection  of  the  murine  promoter  contructs  into  primary  human 
macrophages, S1P1 promoter activation following treatment with AC-CM was 
noticed  only  when  transfecting  the  fragment  containing  -1300  bp  of 
the 5’-flanking region, but not with the -1000 bp fragment (Figure 30).   
 
 
 
Figure  30.  S1P1  promoter  activity  in  macrophages  after  stimulation  with  AC-CM.  Primary 
human macrophages were transfected with the respective reporter constructs and incubated 
with AC-CM for 8 h. Firefly luciferase activity was normalized to Renilla luciferase activity. Data 
are means ± SEM of five independent experiments. Asterisks indicate statistically significant 
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5.8.2  Human and murine S1P1 promoter contain a highly conserved KLF 
binding site 
 
To clarify whether the data obtained using murine promoter contructs can also 
be transferred to the human system, the online-tool TESS was used to compare 
the  human  and  the  murine  S1P1  promoter.  The  sequence  located  between 
-1050 bp and -1300 bp upstream from the transcription start is highly conserved 
between  mice  and  humans  and  contains  three  binding  sites  for  KLF,  a 
transcription  factor,  which  is  known  to  induce  S1P1  expression  (123). 
Interstingly, a sequence spanning 28 bp is completely identical in the human 
and the murine promoter (Figure 31). This sequence, among others, contains a 
binding site for KLF. Thus, this sequence appears likely to be responsible for 
the induction of S1P1 in primary human macrophages.  
 
 
 
Figure 31. Conserved sequence contained  in the human and the murine S1P1 promoter. A 
sequence of 28 bp is completely identical in the human and the murine S1P1 promoter (blue) 
and, among others, contains a KLF binding site (red).  
 
 
5.9  S1P1  is  located  in  pseudopodia-like  structures  of 
macrophages following treatment with AC supernatants 
 
To correlate receptor expression to function its subcellular localization has to be 
considered,  as  signaling  will  only  be  possible  if  the  respective  ligand  is 
available. In the case of S1P receptors, this is of special interest, as they are 
internalized upon treatment with S1P (118). Furthermore, S1P receptors can 
also be cross-activated by growth factors such as PDGF (216) or insulin-like 
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S1P1 in primary human macrophages was located predominantly in the plasma 
membrane and the nucleus (Figure 32). I used the fact that S1P1 is internalized 
upon treatment with S1P to confirm the specificity of the antibody staining of 
S1P1. S1P1 was internalized following incubation with 200 nM S1P for 45 min. 
Interestingly,  S1P1  was  localized  to  the  plasma  membrane,  in  particular  to 
pseudopodia-like structures, after treatment with AC-CM for 6 h.     
 
 
 
Figure 32. S1P1 translocates to pseudopodia-like structures of macrophages in response to 
treatment  with  AC-CM.  Primary  human  macrophages  were  stimulated  with  200  nM  S1P  for 
45 min or with AC-CM for 6 h. Immunofluorescence revealed the localization of S1P1. Nuclei 
were  labeled  by  DAPI-staining.  Displayed  cells  are  representative  of  three  independent 
experiments. Bar indicates 20 µm.    
 
   
5.10  S1P1  is  crucially  involved  in  macrophage  migration  in 
response to AC supernatants 
 
S1P1 and S1P2 have opposing roles in migration. While S1P1 was associated 
with enhanced chemotaxis, S1P2 was shown to counteract this process (83, 5 Results                                                                                                            88                                                                                                                                                                                            
217).  Following  treatment  with  AC-CM,  the  expression  of  S1P1  was  much 
higher than the expression of S1P2 and S1P1 was localized to pseudopodia-like 
structures.  Thus,  it  was  tempting  to  speculate  that  S1P1  could  enhance  the 
migratory  potential  of  macrophages  following  their  exposure  to  AC-CM. 
Therefore,  a  scratch  assay  was  performed  to  analyze  migration  of  primary 
human macrophages in response to treatment with AC-CM. AC-CM fostered 
scratch closure, whereas this was inhibited by the S1P1/3 receptor antagonist 
VPC 23019 (Figure 33 A and B).  
 
 
 
Figure  33.  Enhanced  migration  of  primary  human  macrophages  in  response  to  AC-CM  is 
dependent on S1P receptor. Scratch assay in primary human macrophages incubated with AC-
CM  for  16  h  in  the  presence/absence  of  1  µM  VPC  23019  (A)  and  statistical  analysis  (B). 
Photographs  are  representaitive  of  four  individual  experiments.  Bar  indicates  100  µM. 
Significant differences in scratch width are marked by *p £ 0.05 and ** p £ 0.01. 
 
To confirm that S1P1 was the S1P receptor responsible for migration, I used 
peritoneal  macrophages  from  S1P1  deficient  mice  (Figure  34  A).  While 
macrophages  from  wild-type  mice  showed  migration  in  response  to  AC-CM, 
migration was absent in S1P1 knockout macrophages (Figure 34 B and C).  5 Results                                                                                                            89                                                                                                                                                                                            
 
 
Figure 34. Enhanced migration of primary murine peritoneal macrophages in response to AC-
CM is dependent on S1P1. (A) Knockout of S1P1 in peritoneal macrophages of S1P1 knockout 
mice  was  confirmed  by  Western  blot.  One  representative  blot  out  of  three  individual 
experiments  is  displayed.  Scratch  assay  was  performed  in  primary  murine  macrophages 
derived from wild-type (WT) or S1P1 knockout (KO) mice incubated with AC-CM for 9 h (B) and 
statistically analyzed (C). Photographs are representaitive of seven individual experiments. Bar 
indicates 100 µM. Asterisks indicate statistically significant differences (p £ 0.001). 
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6  DISCUSSION 
 
My  data  provide  evidence  for  S1P1  to  be  a  key  player  during  alternative 
activation of macrophages. Following treatment of primary human macrophages 
with AC-CM, S1P1 was the crucial receptor being responsible for the induction 
of  HO-1,  which  in  turn  increased  the  amount  of  anti-apoptotic  and  anti-
inflammatory  proteins  such  as  Bcl-2  or  Bcl-XL  and  Adora  A2A.  Furthermore, 
S1P1  itself  was  induced  in  macrophages  after  treatment  with  AC-CM  and 
provoked migration of macrophages. 
 
 
6.1  HO-1 contributes to an alternative macrophage activation 
profile induced by apoptotic cell supernatants  
 
The  notion  that  authentic  or AC-derived  S1P  induced  HO-1  is  in  line  with  a 
report by Man and coworkers, showing that the sphingosine analog FTY720 
enhanced  HO-1  expression  (207).  Human  macrophages  express  the  S1P 
receptor subtypes 1-4 (218). Considering that activation of S1P1 attenuated the 
expression  of  pro-inflammatory  cytokines  in  murine  macrophages  (116)  in 
conjunction with the observation that S1P1 signaling in macrophages protected 
from apoptosis (35) fits well to my results, demonstrating that S1P1 provoked an 
increase in HO-1 expression, which in turn triggered anti-apoptotic as well as 
anti-inflammatory signals (Figure 35).  
Inhibitor studies revealed that in primary human macrophages p38 MAPK, a 
pathway well known for HO-1 induction (190, 219), facilitated S1P-evoked HO-1 
expression.  However,  other  studies  have  shown  p38  MAPK  activation 
downstream  of  S1P2  (112),  which  might  explain  that  siRNA-mediated 
knockdown  of  S1P1  could  not  completely  reduce  HO-1  expression  after 
stimulation with AC-CM. This preserves the option that residual S1P2 signaling 
occurred.  
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Figure  35.  Heme  oxygenase-1  contributes  to  an  alternative  macrophage  activation  profile 
induced by apoptotic cell supernatants. Following treatment with supernatants from apoptotic 
cells (AC) macrophages (MF) demonstrate a biphasic expression pattern of heme oxygenase 
(HO)-1.  Whlie  the  first-phase  induction  at  6  h  is  mediated  by  p38  MAPK  (p38)  and  is 
accomplished by AC-derived S1P engaging S1P receptor (S1PR) 1, the second wave of HO-1 
induction  at  24  h  is  attributed  to  autocrine  signaling  of  vascular  endothelial  growth  factor  A 
(VEGFA). Whereas the expression of VEGFA is facilitated by S1P and its release is dependent 
on  STAT1,  VEGFA  itself  acts  on  the  macrophage  HO-1  promoter  via  STAT1/STAT3 
heterodimer binding. HO-1 contributes to alternative macrophage activation by regulating the 
expression of adenosine receptor A2A (Adora A2A), Bcl-XL and Bcl-2. MHC II and indoleamine 
2,3-dioxygenase (IDO) expression are also fostered by AC supernatants, but are not dependent 
on HO-1.        
 
The use of DMS was discussed recently. Besides inhibiting SphK1, DMS also 
has  some  undesirably  side-effects,  such  as  inhibition  of  PKC  (205), 
enhancement of EGF receptor autophosphorylation (220) and even activation of 
SphK2  (221).  As  S1P  mediating  the  anti-apoptotic  effect  of  AC  was  mainly 
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SphK2-deficient Jurkat cells. However, my data with authentic S1P also strongly 
point to S1P being the decisive factor.    
A candidate that would fulfil the characteristics of a transcription factor being 
involved  in  the  early-phase  induction  of  HO-1  might  be  PPAR-g.  Two 
independent  studies  in  RAW264.7  macrophages  revealed  that  PPAR-g  was 
activated following co-culture with apoptotic Jurkat cells for 15 minutes (73) and 
that  the  selective  PPAR-g  agonist  D
12PGJ2-mediated  HO-1  induction  (222). 
Thus, as I observed HO-1 protein expression after 6 h of incubation with AC-
CM, PPAR-g could be the responsible transcription factor. EMSA analysis would 
help to clarify the involvement of PPAR-g in the early-phase HO-1 induction. 
My studies suggest a cross-talk between S1P-signaling and VEGFA secretion 
from  human  macrophages.  A  connection  between  S1P  and  VEGF  signaling 
was recently also put forward for ML-1 thyroid follicular cancer cells as well as 
human FRO anaplastic thyroid cancer cells, in which S1P stimulated VEGFA 
secretion  (223).  Furthermore,  VEGF  secretion  from  epithelial  cells  after 
phagocytosis  of  AC  was  demonstrated  previously  (211).  However,  neither 
signal cross-talk between AC and epithelial cells nor signaling consequences 
were fully understood. In my system, there is evidence for S1P generated by 
AC,  rather  than  cell-cell  contacts  or  phagocytosis,  being  required  for  VEGF 
secretion.  A  connection  between  S1P  and  VEGF  signaling  is  highlighted, 
especially for models of tumor angiogenesis, proposing that tumor-derived S1P 
stimulates  VEGF  formation  in  endothelial  cells  (224,  225).  Macrophages,  as 
cells  in  the  tumor  microenvironment,  are  critical  players  stimulating 
angiogenesis in a variety of human tumors, where they exhibit a pronounced 
alternatively activated anti-inflammatory and anti-apoptotic phenotype (226). My 
finding that VEGFA was not only secreted from macrophages in response to 
S1P, but also caused autocrine signaling to further induce HO-1, implies an 
important role of S1P in macrophage polarization, with particular relevance in 
the tumor setting. Besides mechanisms such as tumor hypoxia, the interaction 
of tumor-associated macrophages with dying tumor cells could then promote 
VEGFA release to stimulate tumor angiogenesis. This proposal is corroborated 
by  the  finding  that  treatment  of  macrophages  with  AC-CM  stimulated 
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expression, which is  an established marker for endothelial cell differentiation 
(227). Differentiation was inhibited in hypoxia inducible factor-1a knockout mice 
and was ascribed to VEGF, which is a target gene of hypoxia inducible factor-
1a. 
When I observed that VEGF expression was induced by S1P via STAT1, it was 
rather an extraordinary finding, as S1P receptor activation had not been linked 
to  STAT  signaling  previously.  I  considered  that  Src  kinase  activation 
downstream  of  a  GPC  receptor  such  as  S1P1  might  be  a  missing 
communication link between S1P and STAT (228), although mechanisms of Src 
activation in response to GPC receptor agonists are not fully understood (229). 
Src kinase activation occurs upstream of STAT signaling in human monocytes 
(230), which led me to the speculation that Src kinase might link S1P receptor 
activation  to  STAT  activation  in  my  system.  Strikingly,  in  rat  aortic  vascular 
smooth  muscle  cells,  the  S1P-stimulated  transactivation  of  STAT-coupled 
epidermal  growth  factor  receptor  and  PDGF-b  receptor  were  Src-dependent 
(231). Recently, it was shown that S1P activates STAT in cardiomyocytes (232). 
Indeed, in this report Src kinase activation was shown to connect S1P to STAT3 
activation. 
STAT3 was necessary for the autocrine induction of HO-1 by VEGF, which was 
observed previously in chronic lymphocytic leukemia B cells (212). Furthermore, 
STAT1 and STAT3 were involved in hyperoxia-induced gene transcription of 
HO-1 in RAW 264.7 macrophages (233). Activation of STATs presumably plays 
an  important  role  in  establishing  an  alternative  macrophage  activation 
phenotype in the tumor setting, because STAT1 is constitutively active in tumor-
associated macrophages (234) and its enhanced signaling properties mediate T 
cell deletion (235). Furthermore, STAT3 and STAT6 are believed to contribute 
to alternative macrophage polarization (236).  
My  work  reveals  that  HO-1  in  macrophages,  besides  accomplishing  anti-
apoptotic functions by enhancing the expression of survival promoting proteins 
such as Bcl-2 and Bcl-XL, also conveys an anti-inflammatory potential, which is 
exemplified by the expression of Adora A2A in response to AC-CM. Adora A2A 
agonists are capable of not only blocking the inflammatory potential of human 
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(237),  but  also promoting  wound-healing  in  disease  states  such as  diabetes 
(238). Likely, in an inflammatory environment, the presence of AC might help to 
promote  healing  once  an  inflammatory  stimulus  is  eliminated  by  modulating 
adaptive immune responses. Thus, successful resolution and repair of tissue 
damage,  rather  than  persistence  of  the  inflammatory  response,  which  can 
promote scarring and loss of organ function, might be provided by AC. In an 
inflammatory environment, neutrophils as a first line of immune defense, are 
rapidly recruited to the site of infection in response to a variety of inflammatory 
stimuli  and  engulf  the  invading  infectious  agents,  after  which  neutrophils 
undergo  apoptosis  (37).  Macrophages,  which  phagocytose  apoptotic 
neutrophils during inflammation, might be protected against apoptosis and the 
expression of Adora A2A could prelude the resolution of inflammation. Today it is 
recognized that at least 15% of tumors worldwide can directly be referred to an 
infectious origin (239) and cancer was considered as an ‘overhealing wound’ 
(240).Thus,  the  induction  of  HO-1  by  AC  could  also  play  an  important  role 
during tumor development, as it seems to play a crucial role in inflammation as 
well as wound-healing. This suggestion is further reinforced by the finding that 
inhibition of HO-1 reduced tumor growth of LL/2 lung cancer in C57BL mice 
(241).  Furthermore,  sphingolipid  metabolism  was  suggested  to  be  often 
dysregulated in cancer (86, 88) and it was proposed that SphK may not only 
protect  tumors  from  apoptosis,  but  may  also  increase  their  vascularization, 
further enhancing growth (88). As discussed before, in my system this could be 
performed by VEGF, which is secreted by macrophages in response to AC-
derived S1P.  
During  the  clearance  of  invading  pathogens,  pro-inflammatory  processes 
ensure maximal immunological activation in the early phase but are followed by 
resolution and active suppression of inflammation (72). The notion that Deta-NO 
induced  Adora  A2A  rather  weakly  compared  to  AC-CM  implies  that  HO-1-
dependent anti-inflammatory effects were only partially mimicked by Deta-NO. 
This may point to the induction of HO-1 by different signaling pathways and 
transcriptional regulators. The induction of HO-1 by NO could be mediated by 
Nrf2 (242), instead of p38 MAPK, which is involved in AC-CM-mediated HO-1 
induction. Likely, Adora A2A is not only induced by HO-1, as I observed some 
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response achieved with AC-CM is rather unique and differs from a situation with 
only  a  pro-inflammatory  stimulus  such  as  LPS  or  NO  to  induce  HO-1 
expression.  Consequently,  in  an  inflammatory  environment,  pro-inflammatory 
stimuli foster the initiation phase of inflammation. However, they might at the 
same time prime for the resolution phase by induction of HO-1, but to a lesser 
extent than AC do and possibly also other target genes of HO-1 are involved. 
Thus, the presence of AC subsequent to or as a result of a pro-inflammatory 
stimulus might be required for the resolution of inflammation.   
According to the suggestions by Zhang and co-workers, enhanced Bcl-2 and 
Bcl-XL expression by HO-1 could be attributed to CO, as shown in a murine 
model of ischemia-reperfusion (243). Generally, several anti-apoptotic effects 
attributed to HO-1 are thought to be CO-mediated (244). This might also apply 
to  Adora A2A,  because  overexpression  of  HO-1  as  well  as  exposure  of 
RAW264.7 macrophages to CO augmented Adora A2A mRNA as well as protein 
expression (245). The rather marginal effect observed with CO and bilirubin in 
my experiments may open a further possibility that HO-1 translocates to the 
nucleus  to  bind  to  a  transcription  factor  or  a  protein  complex,  resulting  in 
enhanced transcription of Adora A2A (246).  
Interestingly, the expression of the anti-inflammatory marker IDO was, at least 
in human macrophages exposed to AC-CM, HO-1-independent. Nevertheless, 
the principle finding that AC-CM augments the expression of IDO is exciting. 
IDO  catalyzes  the  rate-limiting  step  of  tryptophane  degradation.  Kynurenine, 
one of the products of this reaction, affects proliferation as well as differentiation 
of Th cells (247, 248). As IDO was shown to be upregulated by PGE2 (249) and 
COX-2 is also induced in macrophages by AC (80), the induction of IDO by 
COX-derived PGE2 appears likely.  
The development of a macrophage phenotype, which dampens T cell immune 
responses,  was  further  corroborated  by  my  finding  that  macrophages 
downregulate  HLA-DMB  in  response  to  AC.  Although  it  was  reported  that 
bilirubin, a degradation product of biliverdin, suppressed MHC II expression in 
endothelial cells (250), I could not confirm that HLA-DMB expression was HO-1-
dependent  in  macrophages.  This  could  probably  be  referred  to  cell  type 
differences. However, IL-10 being produced either by AC or by macrophages in 
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Reduced expression of HLA-DMB and increased abundance of IDO favor an 
attenuated  response  of  Th1  cells,  which  is  important  to  progress  from 
inflammation towards healing. In this way Adora A2A also plays an important 
role as it is known to convey immunosuppression by inhibiting IL-12 formation 
(237).  IL-12  is  essential  for  the  induction  of  Th1  infammatory  responses, 
provoking  maturation  of  naïve  CD4
+  T  cells  to  Th1  effector  cells  and 
engendering IFN-g secretion by CD8
+ T cells as well as natural killer cells (252).  
Together,  AC  supernatants  provoked  alternative  activation  of  human 
macrophages,  characterized  by  the upregulation  of  Bcl-2, Bcl-XL,  Adora  A2A, 
and IDO, but downregulation of MHC II expression. The establishment of this 
anti-inflammatory phenotype was in part dependent on the induction of HO-1 by 
AC-derived S1P. Thus, targeting HO-1 and/or its downstream effectors could be 
a therapeutic approach to treat patients suffering from diseases linked to anti-
inflammatory macrophage polarization during, e.g. the late immunosuppressive 
phase  of  sepsis  (253)  or  in  cancer  (52),  because  this  would  influence  the 
viability  of  alternative  macrophages  as  well  as  their  polarization.  This  is  of 
special  importance  during  cancer  therapy  as  unfortunately,  HO-1  can  be 
induced  in  response  to  chemotherapy,  radiation  or  photodynamic  therapy, 
which then negatively affects the outcome of the respective therapy (189, 190). 
As the induction of HO-1 during these therapies might be referred to AC-derived 
S1P, it might be a therapeutic advance to drive cancer cells into necrotic cell 
death rather than into apoptosis. Possibly, also interference with the clearance 
of AC could provide a therapeutic approach. Lowering the rate and/or capacity 
of phagocytosis of macrophages could result in the generation of secondary 
necrotic cells, and thus in impaired HO-1 induction. However, problems of these 
approaches  could  be  the  development  of  chronic  inflammation  and 
autoimmunity  (252).  Furthermore,  also  scavenging  of  ROS,  which  constitute 
potential  HO-1  inducers  (149)  and  might  be  generated  during  anti-cancer 
therapies, could prove to be beneficial.  
Interestingly,  HO-1  knockdown  mice  showed  an  accelerated  and  more 
advanced  atherosclerotic  lesion  formation  (254).  HO-1  gene  expression  was 
demonstrated to be enhanced in human arteries with advanced atherosclerosis 
and  was  considered  as  an  adaptive  response  to  injurious  stimuli,  such  as 
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induction in the artery wall scavenged ROS, which lead to the attenuation of 
monocyte adhesion and chemotaxis (256). Furthermore, HO-1 was shown to 
inhibit signaling of TLR 4, the LPS receptor required for classical macrophage 
activation (257). However, the induction of HO-1 during atherosclerosis seems 
not  to  be  sufficient  to  provide  beneficial  effects  and  should  be  targeted 
pharmacologically.  Statins,  whose  effects  were  suggested  to  be  mediated 
indirectly through HO-1 induction (164), form already one therapeutic approach 
to treat atherosclerosis by interfering with HO-1.  
It  is  accepted  nowadays  that  the  presence  of  AC  is  vital  for  the  successful 
resolution  of  inflammation.  Although  dampening  of T  cell  immune  responses 
might  not  be  attributed  to  HO-1,  HO-1  seems  to  play  a  central  role  in  the 
resolution of inflammation. However, HO-1 induction by AC can be beneficial in 
one disease, whereas it proves to be deleterious during another disease, e.g. in 
the case of cancer. Therefore, therapies targeting HO-1 have to be balanced 
thoroughly.    
 
 
6.2  S1P1  is  involved  in  enhanced  motility  of  macrophages 
induced by apoptotic cell supernatants 
 
Following treatment with supernatants from AC, S1P1 was rapidly upregulated 
in macrophages. In particular, mRNA was induced after 1 h and protein after 
3 h. This fits well to the observations of Hla and Maciag, who identified S1P1 as 
an immediate-early gene product, which was induced by phorbol 12-myristate 
13-acetate in human endothelial cells (119). As also S1P1 promoter activity was 
enhanced after incubation with AC-CM, a fast transcriptional process seems to 
be responsible for the induction of S1P1.  
Among  the  potential  candidates,  which  are  possible  as  transcription  factor 
mediating the induction of S1P1, KLF seems to be the most likely one (Figure 
36). KLF2 was considered as a negative regulator of monocyte activation, as it 
inhibited  pro-inflammatory  activation  of  monocytes  and  the  transcriptional 
activity of both NF-kB and AP-1 (258). Since I observed that S1P1 mRNA was 
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of KLF appears more likely than regulation of KLF at the transcriptional level. In 
this way, post-translational modifications serve as a switch for KLF proteins to 
function as activators or repressors. Acetylation of fetal KLF2 by CBP/p300 and 
p300/CBP-associated  factor  enhanced  fetal  KLF2  transcriptional  activity  in 
K562 myelogenous leukemia cells (259). Besides acetylation, modification of 
KLF5  with  SUMO  proteins  was  also  proposed  as  a  means  to  regulate  KLF 
activity (260). Under basal conditions, SUMOylated KLF5 and unligated PPAR-d 
were supposed to interact with co-repressors to form transcriptionally repressive 
complexes.  Ligand  binding  to  PPAR-d  was  suggested  to  initiate  rapid  local 
deSUMOylation,  which  was  followed  by  the  exchange  of  co-regulators, 
chromatin remodelling and activation of transcription. As PPAR was shown to 
be  activated  in  macrophages  in  response  to  treatment  with  AC  (73),  EMSA 
analysis should be performed to prove the involvement of KLF and/or PPAR 
isoforms in the induction of S1P1 following treatment with AC-CM. 
I attributed the unexpected observation of elevated S1P1 expression following 
treatment with AC-CM first to autocrine VEGF, because S1P1 expression was 
increased  in  bovine  aortic  endothelial  cells  after  their  exposure  to  authentic 
VEGF (120). However, mRNA analysis of S1P1 revealed that it was increased 
already after 1 h of incubation with AC-CM. Although VEGF mRNA expression 
was also induced following treatment with AC-CM for 1 h, it is unlikely to act as 
an  autocrine  factor  to  induce  S1P1  expression,  as  autocrine  signaling  would 
require  more  time.  Rather,  an  AC-derived  factor  might  be  important  for  the 
induction of S1P1 expression. In this way, S1P can be ruled out, as S1P1 mRNA 
expression was unaffected following treatment with authentic S1P. Besides AC-
CM, also IL-4 and IL-10, which might be produced by AC (75, 261), provoked 
induction of S1P1 mRNA expression in primary human macrophages. However, 
IL-4 and IL-10 activate STAT signaling rather than KLF (262). As the induction 
of S1P1 mRNA expression was more pronounced in the presence of AC-CM 
than in the presence of IL-4 or IL-10, an additional factor being secreted by AC, 
which induces S1P1 via KLF, seems more likely. To identify this factor, a first 
approach would be to treat AC-CM with proteinase K, DNAse and RNAse and 
to perform a lipid extraction. After identifying the principal nature of this factor, 
these procedures should be followed by more detailed analyses.  
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Figure 36. S1P receptor 1 is involved in migration of macrophages induced by apoptotic cell 
supernatants.  S1P  receptor  1  (S1P1)  and  S1P  receptor  3  (S1P3)  are  upregulated  in 
macrophages  (MF)  following  incubation  with  supernatants  from  apoptotic  cells  (AC).  One 
potential  candidate,  which  is  possible  as  transcription  factor  mediating  S1P1  induction  is 
krüppel-like  factor  (KLF).  S1P1  is  predominatly  localized  to  pseudopodia-like  structures  of 
macrophages.  Autocrine  growth-factor  (GF)  signaling  might  cross-activate  S1P1  via  SphK, 
which generates ‘inside-out’ acting S1P, to induce migration of macrophages into the lymph and 
towards AC along S1P gradients. This step could be crucial for the resolution of inflammation. 
Induction  of  S1P1  by  IL-4  or  IL-10  might  involve  STAT  signaling.  Factors/pathways,  whose 
identification require further studies, are marked with ‘?’.   
 
Activation of S1P1 and S1P3 by S1P is generally associated with stimulation of 
migration,  whereas  activation  of  S1P2  attenuates  this  process  (263).  These 
differences are predominantly referred to the divergent activation of the small 
GTPase Rac (263). Phosphorylation of S1P1 was demonstrated to be essential 
for  Rac  activation,  cortical  actin  assembly,  lamellipodia  formation  and 
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However, S1P2 is considered to inhibit Rac as well as growth-factor induced 
chemotaxis (83). Rho activation occurs downstream of S1P2 as well as S1P3, 
but is considered to be more prominent downstream of S1P2, where it markedly 
inhibits Rac activation (112). In contrast to Rac activation, Rho activation was 
associated  with  the  assembly  of  contractile  actin-myosin  filaments,  so-called 
stress fibers, and associated focal adhesion complexes and thus the inhibition 
of  cell  migration  (264).  These  observations  are  also  true  for  my  studies.  I 
observed formation  of  pseudopodia-like  structures  by  macrophages following 
treatment with AC-CM. Interestingly, S1P1 was located in these structures and 
thus on the cell surface. Consequentely, besides being upregulated, S1P1 was 
located on the plasma membrane to be responsive to S1P and therefore to 
prepare macrophages for further signaling through S1P.  
Gude et al. speculated that recruitment signal gradients sensed by S1P1 might 
regulate  phagocyte  migration  towards  AC  (36).  Consequently,  I  pre-treated 
macrophages  with  AC-CM  for  1  h,  washed  them  with  PBS  and  incubated 
macrophages  in  fresh  medium  with  or  without  the  addition  of  the  S1P1/3 
antagonist  VPC  23019  to  avoid  blocking  of  AC-CM-mediated  autocrine 
signaling. 
As S1P derived from AC-CM might rapidly be ingested by macrophages via 
receptor internalization and degraded by S1P lyase or S1P phosphohydrolase, 
it  can  be  excluded  as  a  crucial  factor  directly  mediating  migration  of 
macrophages.  However,  also  other  AC-derived  factors  can  be  excluded  to 
directly affect migration, as migration was inhibited by VPC 23019 after removal 
of AC-CM. Rather, AC-derived factors might prime macrophages for migration, 
which  then  could  be  mediated  by  the  upregulation  of  S1P1  and  autocrine 
factors. 
As  a  gradient  was  not  present  in  my  system,  macrophages  might  show 
enhanced  motility  as  a  response  to  a  growth  factor  contained  in  the  culture 
medium.  One  potential  candidate  as  a  growth  factor  provoking  migration  of 
macrophages could be PDGF. Transactivation of S1P1 by PDGF was shown to 
mediate  motility  of  human  embryonic  kidney  cells  (216).  This  involved 
stimulation of SphK by PDGF. Intracellularly accumulated S1P was suggested 
to  signal  ‘inside-out’  to  occupy  its  cell  surface  receptors  and  to  modulate 
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lamellipodia extensions, and cell motility induced by PDGF were abrogated in 
S1P1 null fiboblasts (265). In this study, PDGF was shown to stimulate SphK, 
inducing  translocation  of  SphK  to  membrane  ruffles.  Furthermore, 
immunoprecipitation  experiments  suggested  possible  protein  interactions 
between the PDGF receptor and S1P1 (266). Indeed, PDGF was upregulated in 
a whole genome array performed in human macrophages following treatment 
with  AC-CM  (unpublished  data).  Thus,  PDGF  could  be  secreted  by 
macrophages and signal in an autocrine manner to transactivate S1P1 and to 
induce migration of macrophages. 
VEGF, which was secreted by macrophages after incubation with AC-CM, can 
also  be  taken  into  account  as  a  possible  factor  being  responsible  for  the 
migration of macrophages following treatment with AC-CM. There is evidence 
that VEGF can activate SphK1 (86). Nevertheless, it is still not known whether 
S1P, that is generated intracellularly due to VEGF, can occupy cell surface S1P 
receptors  to  regulate  cell  movement  (86).  Another  potential  factor  for  cross-
activation  might  be  insulin-like  growth  factor-1,  which  trans-activated  S1P1 
through phosphorylation (217). However, it remains elusive, whether insulin-like 
growth factor-1 is also secreted by macrophages after treatment with AC-CM.    
In an inflammatory environment, AC could induce S1P1 expression, which might 
enable macrophages to migrate towards the vascular S1P gradient and thus to 
contribute to the resolution of inflammation by recruiting macrophages back into 
the lymph. According to the so-called ‘S1P-S1P1 control-of-lymphocytes model’ 
this process could be ensured by constitutively open endothelial cell junctions 
(267). However, S1P secreted by AC could also serve as a chemoattractant to 
direct macrophages towards AC and thus to ensure efficient clearance of AC. 
Nevertheless,  lymph  levels  of  S1P  are  much  higher  compared  to  those  in 
inflamed tissues. Thus, migration into the lymph might be dominant, although 
migration  towards  AC-derived  S1P  might  simultaneously  occur.  In  an 
inflammatory  environment,  S1P1  will  be  internalized  due  to  the  continuous 
presence  of  AC  and  their  associated  production  of  S1P.  However,  as 
internalization in response to S1P is a reversible process (118) and furthermore 
also  AC-derived  factors  are  present  to  induce  S1P1  continuously,  S1P1  will 
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Besides  clarifying  its  role  in  cross-activation  of  S1P1,  investigating  SphK 
expression and activity in macrophages after treatment with AC-CM would also 
be  very  interesting  considering  the  phagocytic  capacity  of  macrophages. 
Recently, it was indicated that regulatory macrophages, which were induced by 
TLR  agonists and  immune  complexes,  showed  enhanced  SphK1  expression 
(56).  SphK1  was  also  reported  to  be  recruited  to  phagosomes  in  human 
macrophages  (89).  In  phagosomes,  SphK1  can  phosphorylate  sphingosine, 
which  is  produced  in  the  salvage  pathway,  by  hydrolysis  of  membrane 
sphingomyelin. I observed that S1P1 was located in pseudopodia-like structures 
of macrophages treated with AC-CM. However, S1P1 could be internalized into 
phagosomes following phagocytosis of AC. Simultaneously, SphK1 expression 
and/or  activity  could  be  induced,  which  might  provide  high  intraphagosomal 
levels of S1P. Ligation of S1P1 could then enhance the phagocytosis rate of 
macrophages through activation of Rac, which is crucial during phagocytosis (1, 
268), thus fostering the resolution of inflammation. In this case, VEGF could 
also have enhancing potential, as VEGF was also shown to stimulate SphK1 
(86). Thus, S1P and VEGF seem not to be involved in the upregulation of S1P1, 
but may be involved in enhancing the phagocytosis rate and migratory potential 
of macrophages.  
Following incubation with LPS or IFN-g, S1P1 was not induced. This fits well to 
the  observations  provided  by  literature,  as  it  was  demonstrated  that  LPS 
mediated downregulation of S1P1 in marginal zone B cells (269). Despite the 
potential of LPS to induce HO-1, migration of macrophages would be inhibited, 
further scutinizing that the macrophage phenotype induced by pro-inflammatory 
stimuli markly differers from the phenotype induced by AC-CM.  
Investigating the phenomenon of enhanced migration after encounter of AC in 
vascular endothelial cells would also be very interesting. In a tumor environment 
there is a continuous existence of AC, which could secrete factors that foster 
migration  of  vascular  endothelial  cells  directly  or  through  the  ‘macrophage 
relay’, and thus promote angiogenesis. S1P1 is critically involved in endothelial 
cell  biology,  since  S1P1  knockout  mice  died  in  utero  owing  to  vascular 
abnormalities that were caused by the defective migration of vascular smooth 
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Together, the induction of S1P1 following treatment of macrophages with AC-
CM was associated with enhanced motility of macrophages. This could be of 
importance  in  an  inflammatory  environment,  in  which  AC  could  promote  the 
migration of macrophages into the lymph, thus contributing to the resolution of 
inflammation. 
 
 
6.3  Concluding remarks 
 
S1P1 can be considered as a central key player during alternative activation of 
macrophages by provoking increased HO-1 expression, thereby triggering its 
associated anti-apoptotic as well as anti-inflammatory signaling in response to 
AC-derived  S1P.  Furthermore,  S1P1  itself  can  be  upregulated  following 
treatment  with  supernatants  from  AC  and  thereupon  enhance  the  migratory 
potential of macrophages.  
This may be vital for the resolution of inflammation by eliciting anti-inflammatory 
responses  of  macrophages,  which  at  the  same  time  are  protected  against 
apoptosis and show enhanced migratory potential towards AC and the lymph. 
Thus,  efficient  clearance  of  AC  and  trafficking  of  macrophages  out  of  the 
inflammatory environment is ensured. In this way, the presence of AC and/or 
other alternative macrophage activating stimuli prove to be vital, as classical 
macrophage  activating  factors  elicite  only  a  marginal  anti-inflammatory 
response and are also not associated with increased S1P1 expression.    
The  macrophage  phenotype,  which  is  obtained  by  interaction  with  AC,  is 
characterized by anti-inflammatory signaling, which is mediated by Adora A2A as 
well  as  the  inhibition  of  pro-inflammatory  cytokine  production  in  response  to 
LPS treatment (57). Furthermore, this phenotype shows a reduction of MHC II 
expression  and  enhanced  arginase  expression  (70).  Thus,  this  macrophage 
phenotype can be considered as a hybrid-type between alternatively activated 
wound-healing macrophages and regulatory macrophages. Since macrophage 
phenotypes are extremely versatile and depend on the exact composition of the 
respective microenvironment, a detailed understanding of the mechanisms of 
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treat inflammatory disorders. In this regard, interference with S1P1 and/or HO-1 
induction  could  provide  therapeutical  benefits  in  controlling  inflammation, 
autoimmunity, cancer and graft rejection.  
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